WO2012151272A2 - Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique - Google Patents

Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique Download PDF

Info

Publication number
WO2012151272A2
WO2012151272A2 PCT/US2012/036114 US2012036114W WO2012151272A2 WO 2012151272 A2 WO2012151272 A2 WO 2012151272A2 US 2012036114 W US2012036114 W US 2012036114W WO 2012151272 A2 WO2012151272 A2 WO 2012151272A2
Authority
WO
WIPO (PCT)
Prior art keywords
virus
cells
skin
cell
antigen
Prior art date
Application number
PCT/US2012/036114
Other languages
English (en)
Other versions
WO2012151272A3 (fr
Inventor
Thomas S. Kupper
Luzheng Liu
Rachael A. Clark
Original Assignee
Tremrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/099,235 external-priority patent/US8691502B2/en
Application filed by Tremrx, Inc. filed Critical Tremrx, Inc.
Publication of WO2012151272A2 publication Critical patent/WO2012151272A2/fr
Publication of WO2012151272A3 publication Critical patent/WO2012151272A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Vaccines have traditionally consisted of live attenuated pathogens, whole inactivated organisms or inactivated toxins. In many cases these approaches have been successful at inducing immune protection based on antibody mediated responses. Virtually all current vaccines are tested for the capacity to induce a robust antibody response as a surrogate for efficacy.
  • certain pathogens e.g., HIV, HCV, TB, malaria, dengue fever, and cancer, require the induction of T cell-mediated immunity (TCMI).
  • TCMI T cell-mediated immunity
  • Killed vaccines have generally proven ineffective in producing TCMI.
  • live vaccines may induce TCMI, some live attenuated vaccines may cause disease in iramunosuppressed subjects.
  • replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response.
  • the epidermal tissue may be mechanically disrupted by a device such as a scarification needle or an abrader device.
  • the epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine.
  • the vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer.
  • a co-stimulatory molecule, a growth factor, an adjuvant and/or a cytokine is administered before, with or after the viral vaccme.
  • the co-stimulatory molecule is co-expressed with the antigen by the virus.
  • the vaccine will typically be administered to induce a primary response. In some cases, this response will be boosted by one or more subsequent administrations. Examples demonstrate that mice immunized with MVA via skin scarification developed characteristic pox lesions in a dose-dependent manner and generated dose-dependent cellular and humoral immune responses against vaccinia virus (VV) antigens.
  • VV vaccinia virus
  • a kit comprises a device for disrupting a subject's epidermis and the live, modified, non-replicating or replication-impaired virus.
  • FIG. 1 A-D Vaccinia virus inoculation via skin scarification is superiorly immunogenic compared to other immunization routes.
  • C57BL/6 (B6) mice were immunized by VV at 2 x 10 6 pfu dose by the indicated routes, s.s.: skin scarification; i.p.: intraperitoneal injections; s.c:
  • FIG 1 A Primary T cell response: splenocytes harvested on day 7 following immunization (pi.) were restimulated with VV-infected target cells (splenocytes from naive mice) for 6 hours in the presence of brefelding A to measure the frequency of IFN- ⁇ producing CD8 T cells by intracellular cytokine staining. Ul: unimmunized mice.
  • FIG IB Memory VV-specific T cell activity was assessed at 5 week p.i. Splenocytes from immunized mice were restimulated with VV-infected target cells for 48 h and supernatant were harvested. IFN- ⁇ production in supernatant was measured by ELISA.
  • FIG 1C-1D Serum VV-specific IgG level was determined at the indicated time points p.i. by ELISA.
  • FIG. 2 VV skin scarification led to superior protection against secondary cutaneous virus challenge compared to other routes of
  • B6 mice were immunized with VV via various routes as indicated. Eight weeks following immunization, the immune mice were challenged with secondary cutaneous VV infection. Six days after challenge, viral load at the challenged site was measured by real-time PCR.
  • mice Unimmunized mice were included as control.
  • FIG. 3A-D Skin scarification provided superior protection against secondary intranasal viral challenge.
  • FIG. 3A-3B B6 mice were immunized by VV via various routes at 2 c 10 6 pfu dose. Immune mice were lethally challenged with intranasal infection of WR-VV at 6 weeks p.i.. The survival (FIG 3A) and change of bodyweight (BW) (FIG 3B) were monitored daily after challenge.
  • FIG. 3C-3D B6 mice were immunized by VV via skin scarification at the indicated doses, and lethally challenged with intranasal WR-VV infection at 6 weeks pi. The survival (FIG 3C) and change of BW (FIG 3D) were monitored daily after challenge. Unimmunized mice were included as controls.
  • FIG. 4 Immunization via VV skin scarification provides superior protection against intradermal melanoma challenge
  • B6 mice were immunized with rVV-ova via the indicated routes.
  • the immune mice were challenged 4 weeks later with intradermal injection of B 16-ova melanoma cells. Tumor growth was monitored in the challenged mice for up to 40 days and plotted as tumor volume over days post tumor implantation.
  • FIG. 5 A-C T-cell mediated immune response was required for the superior protection against secondary cutaneous challenge following VV skin scarification.
  • WT or B cell deficient mMT mice were immunized with VV via skin scarification or i.p. injection. Mice were then challenged by secondary VV cutaneous infection at 6 weeks p.i..
  • FIG 5A Viral load at the challenged sites were determined on day 6 after challenge. In some groups of wt mice, both CD4 + and CD8 + T cells were depleted before the challenge.
  • FIG 5B-5C Secondary T cell response in challenged wt and mMt immune mice was assessed in skin-draining inguinal lymph nodes and spleen on day 6 following challenged. Skin samples were harvested from the challenged site at 4 days after challenge. Skin-infiltrating CD3 + T cells were identified by immunohistochernistry.
  • FIG. 6A-D T cells but not Ab were important for the prevention of illness, although neither T cells nor B cells were required for survival after lethal intranasal WR-VV challenge.
  • Wild type (wt) or B cell deficient ⁇ mice were immunized with VV via skin scarification (Fig 6A-6B) or i.p. injection (Fig. 6C-6D). Mice were then challenged by lethal WR-VV intranasal infection at 6 weeks pi. In some groups of wt mice, both CD4 + and CD8 + T cells were depleted before and during challenge by large doses of anti-CD4 and anti-CD 8 mAb treatment. Mice survival (Fig. 6 A, 6C) and change of BW (Fig. 6B,6D) were monitored daily after the challenge.
  • FIG. 7A-7D The LN of T cell activation imprints differential expression of skin or gut-homing molecules on CD8 + T cells as early as 60 h after infection.
  • CFSE-labeled Thyl.l + OT-1 cells were adoptively transferred into Thyl.2 B6 mice. Recipient mice were then infected with rVV-ova by either skin scarification or i.p. injection.
  • Fig. 7A 60 hours after the infection, proliferation of OT-1 cells in ILN, and MLN were shown by Histograms gated on Thyl.l + donor cells,
  • b-c ILN of skin scarified mice
  • MLN of i.p.-infected mice Fig.
  • Fig. 7C The geometric mean fluorescence intensities (GMF1) of the indicated markers on OT-1 cells were plotted with the cell division cycles.
  • FIG. 8 Five days after VV skin scarification, T cells activated in skin-draining ILN migrated throughout secondary lymphoid tissues without virus or viral antigen dissemination. RNA samples were prepared from the indicated tissues at day 5 after VV scarification. VV infection was measured by real-time RT-PCT. Data represent the averages + s.d. of 4 independent experiments with three mice per group.
  • FIG. 9A-9C At day 5 after skin scarification with rVV-ova, the gut- homing molecule ⁇ 4 ⁇ 7 was upregulated on disseminated OT-1 CD 8+ cells by secondary homing imprinting. ILN and MLN were harvested at day 5 after scarification with rVV-ova. The expression of the indicated homing markers on Thyl.l 4 OT-1 cells was determined by flow cytometry. Dot plots were gated on Thyl.l "1" cells. B6 mice that had received Thyl.l + OT-1 cells were given daily injections of FTY720 starting 24 h before scarification with rVV-ova.
  • lymphocytes from the indicated tissues were harvested and analyzed by flow cytometry. The percentages of Thy 1.1 + cells in total lymphocytes. (Fig. 9 A), the expression of E-Lig and (Fg. 9B) ⁇ 4 ⁇ 7 (Fig. 9C) on OT-1 cells in ILN were measured.
  • FIG. 10 The primary and secondary imprint of tissue-specific homing molecule during acute viral infection was maintained during the memory phase. Lymphocytes were harvested from the indicated tissues on day 30 after rVV-ova skin scarification. The percentages of E-Lig + or ⁇ 4 ⁇ 7 + cells in Thyl.l 4 OT-1 cells were analyzed by flow cytometry. Data represent the average + s.d. of 6 mice.
  • FIG. 11 A-D MVA immunization via skin scarification (s.s.) elicits dose-dependent immune response.
  • B6 mice were immunized via s.s. with different doses of MVA (from left to right: 1.8 x 10 7 , 1.8 x 10 6 , 1.8 x 10 5 and 1.8 x 10 4 pfu). At day 7 post-immunization, pox lesions were observed in a dose-dependent manner.
  • FIG. 11 A B6 mice were immunized with MVA or VV by s.s. at the indicated doses (pfu / mouse) 7 days post-immunization, primary vaccinia-specific T cell response was measured in spleens.
  • Fig. 11 A B6 mice were immunized with MVA or VV by s.s. at the indicated doses (pfu / mouse) 7 days post-immunization, primary vaccinia-specific T cell response was measured in spleens.
  • FIG. 11 A Serum vaccinia - specific IgG was measured at 6 weeks post- immunization.
  • Fig. 1 IB mice were challenged with lethal i.n. infection with WR-VV at 6 weeks after immunization. Survival (Fig. 11 C) and change of BW (Fig. 1 ID) were monitored daily.
  • FIG. 12A-12F Skin scarification with MVA offers superior immune response and protection efficacy compared to the injection routes.
  • B6 mice were immunized with 2X10 6 pfu MVA by the indicated routes.
  • Fig. 12A Primary T cell response was measured on day 7 p.i.
  • Fig. 12B VV-specific IgG was measured at 6 weeks p.i.
  • Fig. 12C Memory mice were intranasally challenged with lethal dose of WR-VV at 6 weeks p.i. secondary T cell response and post-challenge VV-specific IgG (Fig. 12D) were measured on day 6 challenge.
  • Survival Fig. 12E
  • BW change Fig. 12F
  • FIG. 13A-13C MVA skin scarification is safe even for
  • FIG. 14A is a graph of B-cell-deficient ⁇ mice used to create OT- I : normal parabiotic mice, which were separated surgically 8 weeks PS. 2
  • Fig. 14B is a schematic showing the methodology: 1 day after adoptive transfer of 2*10 6 Thy 1.1+ OT-I cells, the receipt mice were infected with 2x 10 6 PFU VACV-OVA only on the left ears. 20 and 30 days later, some of mice were challenged with 2 l0 6 PFU VACV-OVA on the tail and flank skin, respectively.
  • Fig. 15A and 15B are graphs of the results for B-cell-deficient ⁇
  • mice 6 route. 7 or 30 days later, the immunized mice were challenged with 2x10 PFU VACV on both ears by s.s. route. 1 mg kg FTY720 were
  • Adaptive immune memory that protects against microbial infection is traditionally thought to be mediated by T cells circulating in blood and through secondary lymphoid tissues. According to this view, while memory T cells can be readily mobilized from blood to peripheral epithelial tissues to fight infection, they would return to blood and lymph nodes once the infection was resolved. Very recently, it has been demonstrated that memory T cells can be found in abundance in the peripheral tissues of both humans and mice, with the majority of this work being done in skin. Under normal conditions, twice as many T cells reside in normal human skin as in blood. Skin- homing memory T cells are 20-fold more abundant in normal skin than in blood.
  • TRM skin resident memory T cells
  • TRM skin resident memory T cells
  • cytokines cytokines
  • TRM are not simply memory T cells in an unexpected location. Rather, they are an unique and incompletely characterized population, having many functional and phenotypic qualities that differentiate them from memory T cells that circulate in blood. Similar populations of TRM exist in lung and GI tract, as well as reproductive mucosa.
  • TRM tissue specific T cells
  • a method has been developed based on the discovery that protective immune memory is mediated largely by TRM that have accumulated over time in epithelial tissues.
  • the body has several epithelial surfaces that interface with the environment. The most accessible is skin, but continuous with skin is the oropharyngeal mucosal epithelium, the female reproductive epithelium, and the large and complex epithelial tissues that line the respiratory and gastrointestinal tracts. For pathogens to gain access to blood and internal tissues, they must infect and then breach one or more of these epithelial barriers. While each of these epithelial tissues is structurally different and employs different innate immune defenses, the adaptive immune system mediates lifelong protection against pathogen attack, through T cell memory and B cell antibody production.
  • T R M skin resident T cells
  • TRM peripheral epithelial TRM
  • TCM central memory T cells
  • T cell recruitment into extranodal peripheral tissues is a highly regulated process controlled by the sequential interactions of adhesion molecules and chemokine receptors that are differentially expressed on various T cell subsets and their target.
  • Human skin-homing T cells express cutaneous lymphocyte antigen (CLA) which binds to skin microvasculature- expressed E-selectin, typically in combination with CCR4 whose ligand CCL17 (TARC) is constitutively expressed on skin endothelium.
  • Gut- homing T cells express ⁇ 4 ⁇ 7 integrin and chemokine receptor CCR9, to which the corresponding ligands MadCAM-1 and CCL25 (TEC ) are expressed on the endothelium and epithelium of the small intestine
  • E-Iig and P-lig the functional murine equivalents of human CLA
  • E-Iig and P-lig the functional murine equivalents of human CLA
  • Subsets of proliferating VV specific CD8 T cells leave the draining inguinal node after as few as three cell divisions and migrate through blood to skin (TEM), or to other LN (TCM), respectively.
  • vaccinia- specific TCM cells continue to proliferate, in the absence of continued antigen receptor stimulation, and acquire homing receptors consistent with the regional drainage of the LN they have migrated to; e.g., ⁇ -integrin in mesenteric LN.
  • generalized CD 8 T cell mediated immunity to a local challenge is acquired by systemic dissemination of activated T cells from the local draining LN. The tissue homing properties of these cells then are imprinted in the respective LN environments to which they disseminate.
  • a T cell antigen is a protein or fragement thereof which can be processed into a peptide that can bind to either Class I MHC, Class II MHC, non-classical MHC, or CD1 family molecules (collectively antigen presenting molecules), and in this combination can engage a T cell receptor on a T cell.
  • a B cell antigen is a protein, glycoprotein, carbohydrate, or lipid that can bind to cell surface antibody and can generate the production of soluble antibodies.
  • a T cell mediated immune response is a response that occurs as a result of recognition of a T cell antigen bound to an antigen presenting molecule on the cell surface of an antigen presenting cell, coupled with other interactions between costimulatory molecules on the T cell and APC. This response serves to induce T cell proliferation, anatomic migration, and production of effector molecules, including cytokines and other factors that can injure cells.
  • a humoral immune response is the generation of an immune response that leads to high and sustained levels of circulating antibodies.
  • To treat” or “treatment” of a disease as used herein refers to improving one or more symptoms or the general condition of a subject having the disease.
  • “treating” the cancer refers to inhibiting proliferation or metastasis of a cancer or tumor cells. Treatment may lead to stasis, partial or complete remission of a tumor or may inhibit metastatic spreading of the tumor.
  • treating the infectious disease means reducing the load of the infections agent in the subject.
  • the load may be viral load, and reducing the viral load means, for example, reducing the number of cells infected with the virus, reducing the rate of replication of the virus, reducing the number of new virions produced,or reducing the number of total viral genome copies in a cell, as compared to an untreated subject.
  • the load may be bacterial, yeast, fungi, protozoa, helminths, or parasite load, and reducing such load means, for example, reducing the number of bacteria, fungi, protozoa, helminths, yeast or parasites in a host, reducing the rate of population growth, reducing the spread throughout the subject's body, reducing the amount of toxic products produced by the bacteria, yeast, fungi, protozoa, helminths or parasites, as compared to an untreated subject.
  • To protect or “protection of a subject from developing a disease or from becoming susceptible to an infection as referred herein means to partially or fully protect a subject.
  • to "fully protect” means that a treated subject does not develop a disease or infection caused by an agent such as a virus, bacterium, fungus, protozoa, helminth, and parasites, or caused by a cancer cell.
  • to “partially protect” as used herein means that a certain subset of subjects may be fully protected from developing a disease or infection after treatment, or that the subject does not develop a disease or infection with the same severity as an untreated subject.
  • non-replicating or “replication-impaired” poxvirus refers to a poxvirus that is not capable of replication to any significant extent in the majority of normal mammalian cells or normal primary human cells.
  • the poxvirus has a replication capability of 65%, 55%, 45%, 35%, 25%, or 15% compared to wild-type vaccinia virus.
  • modified virus refers to a poxvirus that has been altered in some way that changes one or more characteristics of the modified virus compared to the wild-type virus. These changes may have occurred naturally or through engineering.
  • the modified virus is altered to include an antigen(s) that are immunogenic (i.e., induce an immune response in a host).
  • Antigens include, for example, cancer antigens or microbial antigens.
  • poxviruses have a large genome, they can readily be used to deliver a wide range of genetic material including multiple genes (i.e., act as a multivalent vector).
  • the sizes of the poxvirus genomes ranges between about 130-300 kbp with up to 300 genes, depending on the strain of the virus. Therefore, it is possible to insert large fragments of foreign DNA into these viruses and yet maintain stability of the viral genome.
  • Poxviruses are useful vectors for a range of uses, for example vaccines to generate immune responses, for the development of new vaccines, for delivery of desired proteins and for gene therapy.
  • the advantages of poxvirus vectors include: (i) ease of generation and
  • Poxviruses can be genetically engineered to contain and express foreign DNA with or without impairing the ability of the virus to replicate.
  • foreign DNA can encode a wide range of proteins, such as antigens that induce protection against one or more infectious agents, immune modulating proteins such as co-stimulatory molecules, or enzymatic proteins.
  • recombinant vaccinia viruses have been engineered to express antigens of herpesvirus, hepatitis B, rabies, influenza, human
  • HIV immunodeficiency virus
  • other viruses Kermand et al., Nature 312:163-6 (1984); Smith et al., Nature 302: 490-5 (1983); Smith et al, Proc. Natl. Acad. Sci. USA 80:7155-9 (1983); Zagury et al., Nature 326:249-50 (1987); Cooney et al. 5 Lancet 337:567-72 (1991); Graham et al, J. Infect. Dis. 166:244-52 (1992), and have been shown to elicit immune responses against influenza virus, dengue virus, respiratory syncytial virus, and human immunodeficiency virus (HIV) when injected.
  • Poxviruses have also been injected to generate immune reactions against tumor-associated antigens such as CEA, PSA and MUC.
  • Poxviruses are well known cytoplasmic viruses.
  • the genetic material expressed by such viral vectors typically remains in the cytoplasm and does not have the potential for inadvertent integration of the genetic material into host cell genes, unless specific steps are taken.
  • the poxvirus vector system will not result in having long term persistence in other cells.
  • the vector and the transformed cells will not adversely affect cells in the host animal at locations distant from the target cell.
  • retrovirus vectors including lentiviral vectors
  • adenoviral vectors adenoviral vectors
  • adeno-associated virus vectors the large genome of poxviruses enables large genes to be inserted into pox-based vectors.
  • a number of poxviruses have been developed as live viral vectors for the expression of heterologous proteins, e.g. attenuated vaccinia virus strains Modified Vaccinia Ankara (MVA) and Wyeth (Cepko et al., Cell 37:1053 1062 (1984); Morin et al., Proc. Natl. Acad. Sci. USA 84:46264630 (1987); Lowe et al, Proc. Natl. Acad. Sci. USA, 84:3896 3900 (1987); Panicali & Paoletti, Proc. Natl. Acad. Sci. USA, 79:4927 4931(1982); Mackett et al., Proc. Natl. Acad.
  • Attenuated vaccinia virus strains include WR strain, NYCBH strain, ACAM2000, Lister strain, LC16m8, Elstree-BNm, Copenhagen strain, and Tiantan strain.
  • Vaccinia virus is the prototype of the genus Orthopoxvirus. It is a double-stranded DNA (deoxyribonucleic acid) virus that has a broad host range under experimental conditions (Fenner et al Orthopoxviruses. San
  • Modified vaccinia virus Ankara (MVA) or derivatives thereof have been generated by long-term serial passages of the Ankara strain of vaccinia virus (CVA) on chicken embryo fibroblasts (for review see Mayr, A., et al., Infection, 3:6-14 (1975).
  • the MVA virus itself may be obtained from a number of public repository sources. For example, MVA was deposited in compliance with the requirements of the Budapest Treaty at CNCM (Institut Pasteur, Collection Nationale de Cultures Microorganisms, 25, rue du Dondel Roux, 75724 Paris Cedex 15) on Dec. 15, 1987 under Depositary No. 1-721 (U.S. Pat. No.
  • MVA virus was deposited in compliance with the Budapest Treaty at the European Collection of Cell Cultures (ECACC) (CAMR, Porton Down, Salisbury, SP4 OJG, UK) on Jan. 27, 1994, under Depository No. V94012707) (U.S. Patent No. 6,440,422 and United States patent publication number 2003/0013190). Also, United States patent publication number 2003/0013190 further discloses particular MVA strains deposited at the ECACC under Depository No. 99101431, and ECACC provisional accession number 01021411. Commercially available are THERION-MV A, THERION PRIFREE vectors and THERION M- SERIES vectors (Therion Biologies Corporation, MA).
  • MVA was generated by 516 serial passages on chicken embryo fibroblasts of the Ankara strain of vaccinia virus (CVA) (Mayr, A., et al. Infection 3, 6-14 [1975]). As a consequence of these long-term passages, about 31 kilobases of the genomic sequence were deleted from the virus (deletion I, II, III, IV, V, and VI) and, therefore, the resulting MVA virus was described as being highly host cell restricted to avian cells (Meyer, H. et al., J. Gen. Virol. 72, 1031-1038 [1991]). It was shown in a variety of animal models that the resulting MVA was significantly avirulent (Mayr, A. & Daraier, K.
  • the virus has a replication capability 5% or less, or 1% or less compared to wild-type virus.
  • Non-replicating viruses are 100% replication deficient in normal primary human cells.
  • Viral replication assays are known in the art, and can be performed for vaccinia virases on e.g. primary keratinocytes, and are described in Liu et al. J.Virol. 2005, 79:12, 7363-70.
  • Viruses which are non-replicating or replication-impaired may have become so naturally (i.e. they may be isolated as such from nature) or artificially e.g. by breeding in vitro or by genetic manipulation, for example deletion of a gene which is critical for replication. There will generally be one or a few cell types in which the viruses can be grown, such as CEF cells for MVA.
  • changes in the virus include, for example, alterations in the gene expression profile of the virus.
  • the modified virus may express genes or portions of genes that encode peptides or polypeptides that are foreign to the poxvirus, i.e. would not be found in a wild-type virus.
  • These foreign, heterologous or exogenous peptides or polypeptides can include sequences that are immunogenic such as, for example, tumor-specific antigens (TSAs), bacterial, viral, fungal, and protozoal antigens, or antigenic sequences derived from viruses other than the viral vector.
  • TSAs tumor-specific antigens
  • the genetic material may be inserted at an appropriate site within the virus genome for the recombinant virus to remain viable, i.e.
  • the genetic material may be inserted at a site in the viral DNA (e.g., nonessential site in the viral DNA) to ensure that the recombinant virus retains the ability to infect foreign cells and to express DNA, while maintaining the desired immunogenicity and diminished virulence.
  • MVA contains 6 natural deletion sites which have been demonstrated to serve as insertion sites. See, for example, U.S. Patent No. 5,185,146, and U.S. Patent No. 6,440,422.
  • genes that code for desired antigens are inserted into the genome of a poxvirus in such a manner as to allow them to be expressed by that virus along with the expression of the normal complement of parent virus proteins.
  • the viruses have a low replicative efficiency in the target cell, which prevents sustained replication and infection of other cells.
  • the modified poxvirus may also have altered characteristics concermng aspects of the viral life cycle, such as target cell specificity, route of infection, rate of infection, rate of replication, rate of virion assembly and/or rate of viral spreading.
  • the inserted gene(s) encoding antigens may be operably linked to a promoter to express the inserted gene.
  • Promoters are well known in the art and can readily be selected depending on the host and the cell type one wishes to target. For example in poxviruses, poxviral promoters may be used, such as the vaccinia 7.5K, 40K, fowlpox.
  • enhancer elements can also be used in combination to increase the level of expression.
  • inducible promoters which are also well known in the art, may be used.
  • Representative poxvirus promoters include an entomopox promoter, an avipox promoter, or an orthopox promoter such as a vaccinia promoter, e.g., HH, 1 IK or Pi.
  • a vaccinia promoter e.g., HH, 1 IK or Pi.
  • the Pi promoter from the Ava I H region of vaccinia, is described in Wachsman et al., J. of Inf. Dis. 155, 1188-1197 (1987). This promoter is derived from the Ava I H (Xho I G) fragment of the L-variant WR vaccinia strain, in which the promoter directs transcription from right to left.
  • the map location of the promoter is approximately 1.3 Kbp (kilobase pair) from the 5' end of Ava IH, approximately 12.5 Kbp from the 5' end of the vaccinia genome, and about 8.5 Kbp 5 * of the Hind III C N junction.
  • the Hind III H promoter (also "HH” and "H6" herein) sequence is an up-stream of open reading frame H6 by Rosel et al., J. Virol 60, 436-449 (1986).
  • the 1 IK promoter is as described by Wittek, J. Virol. 49, 371-378 (1984) and Bertholet, C. et al., Proc. Natl. Acad. Sci. USA 82, 2096-2100 (1985).
  • the promoter is modulated by an external factor or cue, allowing control of the level of polypeptide being produced by the vectors by activating that external factor or cue.
  • heat shock proteins are proteins encoded by genes in which the promoter is regulated by temperature.
  • the promoter of the gene which encodes the metal-containing protein metallothionine is responsive to Cd + ions. Incorporation of this promoter or another promoter influenced by external cues also makes it possible to regulate the production of the polypeptides comprising antigen.
  • the nucleic acid encoding at least one gene of interest encoding is operably linked to an "inducible” promoter.
  • Inducible systems allow careful regulation of gene expression. See, Miller and Whelan, Human Gene Therapy, 8:803-815 (1997).
  • the phrase "inducible promoter” or “inducible system” as used herein includes systems wherein promoter activity can be regulated using an externally delivered agent. Such systems include, for example, systems using the lac repressor from E. coli as a transcription modulator to regulate transcription from lac operator-bearing mammalian cell promoters (Brown et al.
  • Inducible systems are available, e.g., from Invitrogen, Clontech, and Ariad. Systems using a repressor with the operon are preferred. These promoters may be adapted by substituting portions of pox promoters for the mammalian promoter.
  • a "transcriptional regulatory element” or “TRE” is introduced for regulation of the gene of interest.
  • a TRE is a polynucleotide sequence, preferably a DNA sequence, that regulates transcription of an operably-linked polynucleotide sequence by an RNA polymerase to form RNA.
  • a TRE increases transcription of an operably linked polynucleotide sequence in a host cell that allows the TRE to function.
  • the TRE comprises an enhancer element and/or viral promoter element, which may or may not be derived from the same gene.
  • the promoter and enhancer components of a TRE may be in any orientation and/or distance from the coding sequence of interest, and comprise multimers of the foregoing, as long as the desired, transcriptional activity is obtained.
  • an "enhancer" for regulation of the gene of interest is provided.
  • An enhancer is a polynucleotide sequence derived from a gene which increases transcription of a gene which is operably-linked to a promoter to an extent which is greater than the transcription activation effected by the promoter itself when operably-linked to the gene, i.e. it increases transcription from the promoter.
  • a regulatory element such as a TRE or an enhancer generally depends upon the presence of transcriptional regulatory factors and/or the absence of transcriptional regulatory inhibitors.
  • Transcriptional activation can be measured in a number of ways known in the art, but is generally measured by detection and/or quantification of mRNA or the protein product of the coding sequence under control of (i.e., operatively linked to) the regulatory element.
  • the regulatory element can be of varying lengths, and of varying sequence composition.
  • Basal levels are generally the level of activity, if any, in a non-target cell, or the level of activity (if any) of a reporter construct lacking the TRE or enhancer of interest as tested in a target cell type.
  • Certain point mutations within sequences of TREs decrease transcription factor binding and gene activation.
  • One of skill in the art would recognize that some alterations of bases in and around known the transcription factor binding sites are more likely to negatively affect gene activation and cell-specificity, while alterations in bases which are not involved in transcription factor binding are not as likely to have such effects.
  • Certain mutations also increase TRE activity. Testing of the effects of altering bases may be performed in vitro or in vivo by any method known in the art, such as mobility shift assays, or transfecting vectors containing these alterations in TRE functional and TRE non-functional cells. Additionally, one of skill in the art would recognize that point mutations and deletions can be made to a TRE sequence without altering the ability of the sequence to regulate transcription.
  • Any DNA of interest can be inserted into the viral vector described herein.
  • Foreign genes for insertion into the genome of a virus in expressible form can be obtained using conventional techniques for isolating a desired gene.
  • the genes encoding an antigen of interest may be isolated from the genomic DNA; for organisms with RNA genomes, the desired gene may be isolated from cDNA copies of the genome. If restriction maps of the genome are available, strategies can be designed for cleaving genomic DNA by restriction endonuclease digestion to yield DNA fragments that contain the gene of interest. In some cases, desired genes have been previously.
  • nucleic acids are provided that express antigenic domains rather than the entire protein. These fragments may be of any length sufficient to be immunogenic or antigenic. Fragments may be at least four amino acids long, preferably 5-9 amino acids, but may be longer, such as e.g. 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 0, 70, 80, 90, 100, 500 amino acids long or more, or any length in between.
  • Epitopes that induce a protective immune response to a pathogen such as bacteria, viruses, fungi or protozoae or to a cancer antigen may be combined with heterologous gene sequences that encode proteins with immunomodulat ing activities, such as cytokines, interferon type 1 , gamma interferon, colony stimulating factors, interleukin- 1, -2, -4, -5, -6, -12.
  • immunomodulat ing activities such as cytokines, interferon type 1 , gamma interferon, colony stimulating factors, interleukin- 1, -2, -4, -5, -6, -12.
  • At least one nucleic acid fragment encoding a gene is inserted into a viral vector. In another embodiment at least two and up to about ten different nucleic acids encoding different genes are inserted into the viral vector.
  • multiple immunogenic fragments or subunits of various proteins may be used. For example, several different epitopes from different sites of a single protein or from different proteins of the same species, or from a protein ortholog from different species may be expressed.
  • genes of interest are those which encode tumor-associated antigens (TAAs), tumor specific antigens (TSAs), tissue- specific antigens, viral tumor antigens, cellular oncogene proteins, and/or tumor-associated differentiation antigens.
  • TAAs tumor-associated antigens
  • TSAs tumor specific antigens
  • tissue-specific antigens tissue-specific antigens
  • viral tumor antigens cellular oncogene proteins
  • tumor-associated differentiation antigens can serve as targets for the host immune system and elicit responses which result in tumor destruction.
  • This immune response is mediated primarily by lymphocytes; T cells in general and class I MHC-restricted cytotoxic T lymphocytes in particular play a central role in tumor rejection.
  • T-cell activation is often potentiated by providing a suitable immunomodulator, for example a T-cell co-stimulatory factor such as those of the B7 gene family. See e.g., Greenberg, P. D. (1991) in
  • CEA carcinoembryonic antigen
  • PSA prostrate specific antigen
  • antigens include, but are not limited to, melanoma TAAs such as MART-1 (Kawakami et al. J. Exp. Med. 180:347-352, 1994), MAGE-1, MAGE-3, GP-100, (Kawakami et al. Proc. Natl. Acad. Sci. U.S.A. 91 :6458- 6462, 1994), tyrosinase (Brichard et al. J. Exp. Med.
  • TAAs such as MUC- 1 , MUC-2, MUC-3, MUC-4, MUC-18, the point mutated ras oncogene and the point mutated p53 oncogenes (pancreatic cancer), PSA (prostate cancer), c-erb/B2 (breast cancer), KS 1/4 pan-carcinoma antigen (Perez and Walker, 1990, J. Immunol. 142:3662-3667; Bumal, 1988, Hybridoma 7(4):407-415), ovarian carcinoma antigen (CA125) (Yu et al., 1991, Cancer Res. 51(2):468-475), prostatic acid phosphate (Tailor et al.
  • ganglioside GM2 Livingston et al., 1994, J. Clin. Oncol. 12:1036-1044
  • ganglioside GM3 Hoon et al, 1993, Cancer Res. 53:5244-5250
  • tumor-specific transplantation type of cell-surface antigen TSTA
  • virally-induced tumor antigens including T-antigen DNA tumor viruses and Envelope antigens of RNA tumor viruses
  • bladder tumor oncofetal antigen Hellstrom et al, 1985, Cancer. Res. 45:2210-2188
  • differentiation antigen such as human lung carcinoma antigen L6, L20 (Hellstrom et al, 1986, Cancer Res. 46:3917-3923), antigens of
  • fibrosarcoma human leukemia T cell antigen-Gp37 (Bhattacharya-Chatterjee et al., 1988, J. of Immuno specifically. 141:1398-1403), neoglycoprotein, sphingolipids, breast cancer antigen such as EGFR (Epidermal growth factor receptor), HER2 antigen (p ⁇ S5 mR2 ), polymorphic epithelial mucin (PEM) (Hilkens et al, 1992, Trends in Bio. Chem. Sci.
  • malignant human lymphocyte antigen-APO- 1 (Bernhard et al, 1989, Science 245:301-304), differentiation antigen (Feizi, 1985, Nature 314:53-57) such as I antigen found in fetal erythrocytes, primary endoderm, I antigen found in adult erythrocytes, preimplantation embryos, I(Ma) found in gastric
  • adenocarcinomas Ml 8, M39 found in breast epithelium, SSEA-1 found in myeloid cells, VEP8, VEP9, Myl, VIM-D5, Di S6 clearance 22 found in colorectal cancer, TRA-1-85 (blood group H), C14 found in colonic adenocarcinoma,
  • F3 found in lung adenocarcinoma AH6 found in gastric cancer, Y hapten, Le y found in embryonal carcinoma cells, TL5 (blood group A), EGF receptor found in A431 cells, Ei series (blood group B) found in pancreatic cancer, FC10.2 found in embryonic carcinoma cells, gastric adenocarcinoma antigen, CO-514 (blood group Le a ) found in Adenocarcinoma, NS-10 found in adenocarcinomas, CO-43 (blood group Le b ), G49 found in EGF receptor of A431 cells, MH2 (blood group ALe b /Le y ) found in colonic adenocarcinoma, 19.9 found in colon cancer, gastric cancer mucins, T 5 A7 found in myeloid cells, R.24 found in melanoma, 4.2, GD3 > DO, OFA-1, GM 2 , OFA-2, GD2 > and Ml :22:25:
  • CR2, CR3, CR4, C3a/C4a receptor C5a receptor
  • Epstein-Barr Virus antigens (EBNA) BZLF-1
  • BXLF-1 BXLF-1
  • Nuclear Matrix Proteins modified TAAs or TSAs, splice variants of TAAs or TSAs, functional epitopes, epitope agonists, and degenerate nucleic acid variations thereof.
  • Influenza influenza virus hemagglutinin (Genbank accession no. J02132; Air, 1981, Proc. Natl. Acad. Sci. USA 78:7639-7643; Newton et al., 1983, Virology 128:495-501), influenza virus neuraminidase, PBl, PB2, PA,
  • Adenovirus E1A, E1B, E2, E3, E4, E5, L1.-L2, L3, L4, L5
  • Pneumonovirinae e.g., pneumovirus, human respiratory syncytial virus
  • Papovaviridae polyomavirus and papillomavirus: El, E2, E3, E4, E5a, E5b, E6, E7, E8, L1, L2
  • Human respiratory syncytial virus human respiratory syncytial virus: G glycoprotein (Genbank accession no. Z33429; Garcia et al., 1994, J. Virol; Collins et al., 1984, Proc. Natl. Acad. Sci. USA 81 :7683), RSV-viral proteins, e.g., RSV F glycoprotein,
  • Dengue virus core protein, matrix protein or other protein of Dengue virus (Genbank accession no. Ml 1 7; Hahn et al., 1 88, Virology 162:167-180),
  • Measles measles virus hemagglutinin (Genbank accession no.
  • Herpesviridae e.g., herpes simplex virus 1, herpes simplex virus 2, herpes simplex virus 5, and herpes simplex virus 6: herpes simplex virus type 2 glycoprotein gB (Genbank accession no. M14923; Bzik et al., 1986, Virology 155:322-333), gB, gC, gD, and gE, HIV (GP-120, pi 7, GP-1 0, gag, pol, qp41 5 g l20, vif, tat, rev, nef, vpr, vpu, vpx antigens),
  • herpes simplex virus type 2 glycoprotein gB Genbank accession no. M14923; Bzik et al., 1986, Virology 155:322-333
  • gB, gC, gD, and gE HIV (GP-120, pi 7, GP-1 0, gag, pol, qp41 5 g l
  • Lentivirus e.g. human immunodeficiency virus 1 and human immunodeficiency virus 2 envelope glycoproteins of HIV I (Putney et al., 1986, Science 234:1392-1395)
  • Picomaviridae e.g., enterovirus, rhinovirus, hepatovirus (e.g., human hepatitis A virus)
  • Reoviridae (orthoreovirus, orbivirus, rotavirus, cypo virus, fijivirus, phytoreovirus, and oryzavirus),
  • Retroviridae (mammalian type B retroviruses, mammalian type C retroviruses, avian type C retroviruses, type D retrovirus group, BLV-HTLV retroviruses)
  • Spumavirus flaviviridae (e.g., hepatitis C virus), hepadnaviridae (e.g., hepatitis B virus), togaviridae (e.g., alphavirus (e.g., Sindbis virus) and rubi virus (e.g., rubella virus), rhabdoviridae (e.g., vesiculovirus, lyssavirus, ephemerovirus, cytorhabdovirus, and necleorhabdovirus), arenaviridae (e.g., arenavirus, lymphocytic choriomeningitis virus, Ippy virus, and lassa virus), and coronaviridae (e.g., coronaviras and torovirus).
  • flaviviridae e.g., hepatitis C virus
  • hepadnaviridae e.g., hepatitis B virus
  • Poliovirus I VP1 (Emini et al., 1983, Nature 304:699)
  • Hepatitis B virus hepatitis B surface antigen (Itoh et al., 1986,
  • Hep B Surface Antigen gp27 s , gp36 s , gp42 s , p22 c , pol, x
  • Adenovirdiae (mastadenovirus and aviadenovirus)
  • Poxyiridae e.g., chordopoxyirinae, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipoxvirus, and entomopoxyirinae
  • Papovaviridae polyomavirus and papillomavirus
  • Paramyxoviridae paramyxovirus, parainfluenza virus 1
  • metapneumovirus e.g., avian pneumovirus and human
  • Pseudorabies pseudorabies virus g50 (gpD), pseudorabies virus II (gpB), pseudorabies virus gill (gpC), pseudorabies virus glycoprotein H, pseudorabies virus glycoprotein E,
  • Transmissible gastroenteritis transmissible gastroenteritis glycoprotein 195, transmissible gastroenteritis matrix protein,
  • Newcastle virus Newcastle disease virus hemagglutinin- neuraminidase
  • infectious laryngotracheitis virus infectious laryngotracheitis virus glycoprotein G or glycoprotein 1
  • La Crosse virus a glycoprotein of La Crosse virus (Gonzales-
  • Swine viruses including:
  • swine rotavirus glycoprotein 38 swine parvovirus capsid protein
  • Serpulina hydodysenteriae protective antigen bovine viral diarrhea glycoprotein 55, neonatal calf diarrhea virus (Matsuno and Inouye, 1983, Infection and hnmunity 39:155)
  • hog cholera virus African swine fever virus
  • swine influenza swine flu hemagglutinin and swine flu
  • Equine viruses including:
  • equine influenza virus or equine herpesvirus equine influenza virus type A/ Alaska 91 neuraminidase, equine influenza virus type A/Miami 63 neuraminidase, equine influenza virus type A/Kentucky 81 neuraminidase, equine herpesvirus type 1 glycoprotein B, and equine herpesvirus type 1 glycoprotein D,
  • Cattle viruses including:
  • Bovine respiratory syncytial virus or bovine parainfluenza virus bovine respiratory syncytial virus attachment protein (BRSV G), bovine respiratory syncytial virus fusion protein (BRSV F), bovine respiratory syncytial virus nucleocapsid protein (BRSV N), bovine parainfluenza virus type 3 fusion protein, and bovine parainfluenza virus type 3 hemagglutinin neuraminidase), bovine viral diarrhea virus glycoprotein 48 or glycoprotein 53, infectious bovine rhinotracheitis virus: infectious bovine rhinotracheitis virus glycoprotein E or glycoprotein G, foot and mouth disease virus, punta toro virus (Dalrymple et al, 1981, in Replication of Negative Strand Viruses, Bishop and Compans (eds.) s Elsevier, N.Y., p. 167),
  • the antigenic or immunogenic protein fragment or epitope may be derived from a pathogenic bacteria such as
  • Chlamydia Chlamydia protease-like activity factor (CPAF), major outer membrane protein (MOMP)
  • Legionella Legionella peptidoglycan-associated lipoprotein (PAL), mip, flagella, OmpS, hsp60, major secretory protein (MSP)
  • PAL peptidoglycan-associated lipoprotein
  • MSP major secretory protein
  • Diptheria diptheria toxin (Audibert et al, 1981, Nature 289:543) Streptococcus 24M epitope (Beachey, 1985, Adv. Exp. Med. Biol. 185:193)
  • Gonococcus gonococcal pilin (Rothbard and Schoolnik, 1985, Adv. Exp. Med. Biol. 185:247)
  • Mycoplasm mycoplasma hyopneumoniae.
  • Mycobacterium tuberculosis M. tuberculosis antigen 85 A, 85B, MPT51, PPE44, mycobacterial 65-kDa heat shock protein (DNA-hsp65), 6- kDa early secretary antigenic target (ES AT-6)
  • Salmonella typhi Salmonella typhi
  • Yersinia perstis Y. pestis low calcium response protein V (LcrV), Fl and Fl-V fusion protein
  • Salmonella SpaO and HI a, outer membrane proteins (OMPs);
  • Pseudomonas P.aeruginosa OMPs, PcrV, OprF, Oprl, PilA and mutated ToxA
  • the antigenic or immunogenic protein fragment or epitope may be derived from a pathogenic fungus, including but not limited to:
  • Coccidioides immitis Coccidioides Ag2/Pral06, Prp2,
  • Blastomyces dermatitidis Blastomyces dermatitidis surface adhesin
  • Cryptococcus neoformans Cryptococcus neoformans GXM and its Peptide mimotopes, and mannoprotems, Cryptosporidiums surface proteins gpl5 and gp40, Cp23 antigen, p23
  • Aspergillus species Aspergillus Asp f 16 , Asp f 2, Der p 1, and Fel d
  • the antigenic or immunogenic protein fragment or epitope may be derived from a pathogenic protozoan, such as, for example:
  • Plasmodium falciparum Plasmodium falciparum
  • Plasmodium vivax Plasmodium ovale
  • Plasmodium malariae Plasmodium apical membrane antigen 1 (AMA1), 25- kDa sexual-stage protein (Pfs25), erythrocyte membrane protem 1 (PfEMPl) circumsporozoite protein (CSP), Merozoite Surface Protein- 1 (MSP1 )
  • Leishmania species include Leishmania cysteine proteinase type III (CPC) Trypanosome species (African and American): T. pallidum outer membrane lipoproteins, Trypanosome beta-tubulin (STIB 806), microtubule- associate protein (MAP pi 5), cysteine proteases (CPs)
  • CPC cysteine proteinase type III
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T. pallidum outer membrane lipoproteins
  • T. pallidum outer membrane lipoproteins T.
  • Pneumocystis carinii Pneumocystis carinii major surface
  • Schistosomiasis Schistosomiasis mansoni Sml4, 21.7 and SmFim antigen, Tegument Protein Sm29, 26kDa GST, Schistosoma japonicum, SjCTPI, SjC23, Sj22.7, or SjGST-32
  • Toxoplasmosis gondii surface antigen 1 (TgSAGl), protease inhibitor-1 (TgPI-1), surface-associated proteins MIC2, MIC3, OP2, GRA1-GRA7.
  • the recombinant viruses express antigens to elicit an immune response in a subject as well as cytokines or co-stimulatory molecules.
  • cytokines e.g., IL-1
  • co-stimulatory molecules e.g., IL-2
  • IFN interferon
  • GM-CSF granulocyte macrophage colony stimulating factor
  • accessory molecule e.g. ICAM-1
  • co-stimulatory molecules e.g., B7.1, B7.2
  • either cytokines, co-stimulatory or other immunomodulatory molecules can be co-administered via co-insertion of the genes encoding the molecules into the recombinant vector or a second recombinant virus which is admixed with the recombinant virus expressing the antigen.
  • the cytokines can be administered separately, systemically to the host. It may be desirable to administer a substantially pure preparation of the immunomodulator to boost vaccine efficacy.
  • costimulatory molecules include, but are not limited to, B7-1, B7-2, ICAM-1, CD40, CD40L, LFA-3, CD72, OX40L (with or without OX40).
  • cytokines and growth factors include but are not limited to: granulocyte macrophage-colony stimulating factor (GM- CSF), granulocyte-colony stimulating factor (G-CSF), macrophage-colony stimulating factor (M-CSF), tumor necrosis factors (TNFa and TNF ), transforming growth factors (TGFa and TGFp), insulin-like growth factors (IGF-I and IGF-II), growth hormone, interleukins 1 to 15 (IL-1 to IL-15), interferons ⁇ , ⁇ , ⁇ (IFN-a IFN- ⁇ and IFN- ⁇ ), brain-derived neurotrophic factor, neurotrophins 3 and 4, hepatocyte growth factor, erythropoietin, EGF- like mitogens, TGF-like growth factors,
  • the co-stimulatory molecule, growth factor, adjuvant or cytokine is IL-1, IL-2, IL-4, IL-7, IL1-9, IL-12, IL-15, IL-18, IL-23, IL-27, IL-31, IL-33, B7-1, B7-2, B7-H3, LFA-3, B7- H3, CD40, CD40L, ICOS-ligand, OX-40L, 4-1BBL, GM-CSF, SCF, FGF, Flt3-ligand, CCR4, QS-7, QS-17, QS-21, CpG oligonucleotides, ST-246, AS-04, LT Rl 92G mutant, Monta ide ISA 720, heat shock proteins, synthetic mycobacterial cordfactor (CAF01), Lipid A mimetics, Salmonella enterica serovar Typhimurium flagellin (FliC), Montanide 720, Levamisole (LMS), Im
  • poxviruses expressing B7-1, ICAM-1, and LFA-3 also known as TRICOM, are provided that induce activation of both CD4 + and CD8 + T cells.
  • OX40 is a primary co-stimulator of T cells that have encountered antigen, rather than naive T cells, and promotes T-cell expansion after T cell tolerance is induced.
  • OX40L plays a role during T cell activation by a) sustaining the long-term proliferation of CD4 + and CD8 + T cells, b) enhancing the production of Thl cytokines such as IL-2, IGN- ⁇ , and TNF-a from both CD4 + and CD8 + T cells without changing IL-4 expression, c) protecting T cells from apoptosis.
  • the combination of B7-1, ICAM-1, LFA-3, and OX40L enhances initial activation and then further potentiates sustained activation of naive and effector T cells.
  • Adjuvants can also be administered.
  • the poxvirus also contains OX40L.
  • Other useful adjuvants that can be administered separately from the poxvirus are, for example, RIBI Detox (Ribi Immunochemical), QS21 (Aquila), incomplete Freund's adjuvant.
  • the recombinant viruses are administered in the form of a composition including one or more other pharmaceutically acceptable carriers, including any suitable diluent or excipient.
  • the pharmaceutically acceptable carrier does not itself induce a physiological response, e.g., an immune response nor result in any adverse or undesired side effects and/or does not result in undue toxicity.
  • Pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, and combinations thereof. Additional examples of pharmaceutically acceptable carriers, diluents, and excipients are provided in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J., current edition.
  • the DNA donor vector contains the following elements: (i) a prokaryotic origin of replication, so that the vector may be amplified m a prokaryotic host; (if) a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector (e.g., a gene encoding antibiotic resistance); (iii) at least one gene encoding a desired protein located adjacent to a transcriptional promoter capable of directing the expression of the gene; and (iv) DNA sequences homologous to the region of the parent virus genome where the foreign gene(s) will be inserted, flanking the construct of element (iii).
  • a prokaryotic origin of replication so that the vector may be amplified m a prokaryotic host
  • a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector e.g., a gene encoding antibiotic resistance
  • Genes encoding an antigen of interest can be amplified by cloning the gene into a bacterial host.
  • various prokaryotic cloning vectors can be used. Examples are plasmids pBR322 and pEMBL.
  • the cloned genes can be excised from the prokaryotic cloning vector by restriction enzyme digestion.
  • the DNA fragment carrying the cloned gene can be modified as needed, for example, to make the ends of the fragment compatible with the insertion sites of the poxvirus vectors, then purified prior to insertion into these vectors at restriction endonuclease cleavage sites (cloning sites).
  • the DNA gene sequence to be inserted into the virus can be placed into a plasmid, e.g., an E. coli plasmid construct, into which DNA homologous to a section of DNA such as that of the poxvirus has been inserted.
  • a plasmid e.g., an E. coli plasmid construct
  • the DNA gene sequence to be inserted is ligated to a promoter.
  • the promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA which is the desired insertion region.
  • the resulting plasmid construct is then amplified by growth within E. coli bacteria and isolated.
  • the plasmid also contains an origin of replication such as the E. coli origin of replication, and a marker such as an antibiotic resistance gene for selection and propagation in E. coli.
  • the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g., chick embryo fibroblasts, along with the poxvirus. Recombination between homologous pox DNA in the plasmid and the viral genome respectively results in a poxvirus modified by the presence of the promoter-gene construct in its genome, at a site which does not affect virus viability.
  • the gene(s) IS inserted into a site or region
  • insertion region in the virus which does not significantly affect viability of the resultant recombinant virus, e.g. intragenic regions between viral genes, preferably non-essential viral genes.
  • the skilled artisan can readily identify such regions in a virus by, for example, testing segments of virus DNA for regions that allow recombinant formation without seriously affecting virus viability of the recombinant.
  • insertion regions include, for example, BamHI J (Jenkins, et al, AIDS Research and Human-Retrovirases 7:991-998 (1991)) the EcoRI-Hindlll fragment, BamHI fragment, EcoRV-HindHIII fragment,
  • all DNA fragments for construction of the donor vector including fragments containing transcriptional promoters and fragments containing sequences homologous to the region of the parent virus genome into which foreign genes are to be inserted, can be obtained from genomic DNA or cloned DNA fragments.
  • the donor plasmids can be mono-, di ⁇ , or multivalent (i.e., can contain one or more inserted foreign gene sequences).
  • the donor vector may contain an additional gene which encodes a marker which will allow identification of recombinant viruses containing inserted foreign DNA.
  • marker genes can be used to permit the identification and isolation of recombinant viruses. These include, for example, genes that encode antibiotic or chemical resistance (e.g., see Spyropoulos et al, J. Virol., 62:1046 (1988); Falkner and Moss., J. Virol., 62:1849 (1988); Franke et al, Mol. Cell. Biol, 5:1918 (1985), as well as genes such as the E. coli lacZ gene, that permit identification of recombinant viral plaques by colorimetric assay (Panicali et al., Gene, 47:193 199 (1986)).
  • Homologous recombination between donor plasmid DNA and viral DNA in an infected cell results in the formation of recombinant viruses that incorporate the desired elements.
  • Appropriate host cells for in vivo recombination are generally eukaryotic cells that can be infected by the virus and transfected by the plasmid vector. Examples of such cells suitable for use with a poxvirus are chick embryo dermal (CED) cells, HuTK143 (human) cells, and CV-1 and BSC-40 (both monkey kidney) cells. Infection of cells with poxvirus and transfection of these cells with plasmid vectors is accomplished by techniques standard in the art (Panicali and Paoletti, U.S. Pat. No.
  • the donor DNA can be directly ligated into the parental virus genome at a unique restriction site (Scheiflinger, et al. (1992) Proc. Natl. Acad. Sci. (USA) 89:9977 9981).
  • recombinant viral progeny can be identified by several techniques well known in the art. For example, if the DNA donor vector is designed to insert foreign genes into the parent virus thymidine kinase (TK) gene, viruses containing integrated DNA will be TK " and can be selected on this basis (Mackett et al., Proc. Natl Acad. Sci. USA, 79:7415 (1982)). Alternatively, co-integration of a gene encoding a marker or indicator gene with the foreign gene(s) of interest, as described above, can be used to identify recombinant progeny.
  • One preferred indicator gene is the E. coli lacZ gene: recombinant viruses expressing ⁇ - galactosidase can be selected using a chromogenic substrate for the enzyme (Panicali et al., Gene, 47:193 (1986)).
  • the cells used for wmslvaccine production may be cell lines, i.e. cells that grow continuously in vitro, either as single-cell suspension culture in bioreactors or as a monolayer on a cell- support surface of tissue culture flasks or roller-bottles.
  • Primary animal cells may be used for the manufacture of vaccines. For example,
  • chordopoxvirinae in particular MVA are amplified in cell cultures of primary or secondary chicken embryo fibroblasts (CEF).
  • the cells are obtained from embryos of chicken eggs that are incubated for 10 to 12 days. The cells of the embryos are then dissociated and purified. These primary CEF cells can either be used directly or after one further cell passage as secondary CEF cells. Subsequently, the primary or secondary CEF cells are infected with the MVA. For the amplification of MVA the infected cells are incubated for 2-3 days at 37°C. (see, e.g., Meyer, H. et al. 1991; J. of General Virology 72, 1031-1038; Sutter et al. 1994, Vaccine, Vol. 12, No.
  • CEF cells are often used since many virus vaccines are made by attenuating the virulent disease-causing virus by serially passaging in CEF cells.
  • Attenuated viruses, such as MVA are preferably not propagated on human cells since there is a concern that the viruses might become replication competent in cells of human origin. Viruses that have regained the ability to replicate in human cells represent a health risk if administered to humans, in particular if the individuals are immune compromised. For this reason, some attenuated viruses, such as MVA, are strictly manufactured from CEF cells, if intended for human use.
  • CEF cells are used for those viruses that grow only in these cells, for example avian viruses such as avipox viruses, canary pox virus, ALVAC, Fowl pox virus and NYVAC.
  • host cells such as epidermal epithelial cells, fibroblasts, or dendritic cells, infected with the recombinant viruses express the antigen(s) and may additionally express the immuno stimulatory molecule(s).
  • the antigen may be expressed at the cell surface of the infected host cell.
  • the immunostimulatory molecule may be expressed at the cell surface or may be actively secreted by the host cell.
  • both the antigen and the immunostimulatory molecule may provide the necessary MHC restricted peptide to specific immunosurveilling T cells and the appropriate signal to the T cell in the skin to aid in antigen recognition and proliferation or clonal expansion of antigen specific T cells.
  • the overall result may be an upregulation of the immune system.
  • the upregulation of the immune response is an increase in antigen specific T-helper lymphocytes and/or cytotoxic lymphocytes, including for example, Thl or Th2 CD4 + T-helper cell- mediated or CD8 + cytotoxic T-lymphocytes, which are able to kill or inhibit the growth of a disease causing agent (such as a cancer cell) or a cell infected with a disease causing agent (such as a cell infected with a virus, a bacteria, a fungus, or a protozoa.
  • the immune stimulation may also involve an antibody response comprising generations of one or more antibody classes, such as IgM, IgG, and/or IgA.
  • a variety of methods well known in the art can be used to assay the expression of the polypeptide encoded by the inserted gene. These methods include, for example, black plaque assay (an in situ en:zyme immunoassay performed on viral plaques), Western blot analysis, radioimmunoprecipitation (RIP A), enzyme
  • EIA immunoassay
  • CTL assay functional assay
  • a subject in need of treatment is a subject having or at risk of having cancer or a subject having or at risk of having an infection (e.g., a subject having or at risk of contracting a viral, bacterial, fungal or protozoal infection).
  • a subject having cancer is a subject that has detectable cancerous cells.
  • Cancer refers to an uncontrolled growth of cells which interferes with the normal functioning of the bodily organs and systems.
  • a subject at risk of developing a cancer is one who has a higher than normal probability of developing cancer. These subjects include, for instance, subjects having a genetic abnormality, the presence of which has been demonstrated to have a correlative relation to a higher likelihood of developing a cancer. These subjects also include subjects exposed to cancer causing agents (i.e., carcinogens) such as tobacco, asbestos, or other chemical toxins, or subjects who have previously been treated for cancer and are in apparent remission.
  • cancer causing agents i.e., carcinogens
  • a subject having an infection is a subject that has been exposed to an infectious microorganism and has acute or chronic detectable levels of the microorganism in his/her body or has signs and symptoms of the infectious microorganism.
  • Methods of assessing and detecting infections in a subject are known by those of ordinary skill in the art.
  • a subject at risk of having an infection is a subject that may be expected to come in contact with an infectious microorganism. Examples of such subjects are medical workers or those traveling to parts of the world where the incidence of infection is high.
  • the subject is at an elevated risk of an infection because the subject has one or more risk factors to have an infection.
  • risk factors to have an infection include, for example, immunosuppression, immunocompromise, age, trauma, burns (e.g., thermal burns), surgery, foreign bodies, cancer, newborns especially newborns born prematurely.
  • the degree of risk of an infection depends on the multitude and the severity or the magnitude of the risk factors that the subject has.
  • Risk charts and prediction algorithms are available for assessing the risk of an infection in a subject based on the presence and severity of risk factors.
  • the subject who is at an elevated risk of an infection may be an apparently healthy subject.
  • An apparently healthy subject is a subject who has no signs or symptoms of disease.
  • viruses that can be treated by the methods described herein, or for which the methods described herein confer protection, include, but are not limited to, HIV, influenza, dengue, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Human papilloma virus, Ebola, Marburg, Rabies, Hanta virus infection, West Nile virus, SARS-like Coronavirases, Herpes simplex virus (HSV1 and HSV2), Varicella-zoster virus, Epstein-Barr virus, Human herpesvirus 8, Alpha viruses, St. Louis encephalitis.
  • HIV HIV
  • influenza dengue
  • Hepatitis A virus Hepatitis B virus
  • Hepatitis C virus Human papilloma virus
  • Ebola Marburg
  • Rabies Hanta virus infection
  • West Nile virus West Nile virus
  • SARS-like Coronavirases Herpes simplex virus (HSV1 and HSV2)
  • Varicella-zoster virus Epstein-Barr virus
  • enteroviruses including, but not limited to, viruses that the family picornaviridae, such as polio virus, Coxsackie virus, echo virus
  • rotaviruses rotaviruses
  • adenovirus adenovirus
  • hepatitis virus such as hepatitis A, B, C D and E.
  • Retroviridae e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and other isolates, such as HIV-LP; Picornaviridae (e.g., polio viruses, hepatitis A virus; enteroviruses, human Coxsackie viruses, rhinoviruses, echoviruses); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis viruses, rubella viruses); Flaviviridae (e.g., encephalitis viruses, yellow fever viruses); Coronaviridae (e.g., coronaviruses);
  • Retroviridae e.g., human immunodeficiency viruses, such as HIV-1 (also referred to as HTLV-III, LAV or HTLV-III/LAV, or HIV-III; and
  • Rhabdoviridae e.g., vesicular stomatitis viruses, rabies viruses
  • Filoviridae e.g., vesicular stomatitis viruses, rabies viruses
  • ebola viruses ebola viruses
  • Paramyxoviridae e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus
  • Orthomyxoviridae e.g., influenza viruses
  • Bunyaviridae e.g., bunya viruses, phleboviruses and Nairo viruses
  • Arenaviridae hemorrhagic fever viruses
  • Reoviridae e.g., reoviruses, orbiviurses and rotaviruses
  • Birnaviridae Hepadnaviridae (Hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae
  • papillomaviruses polyoma viruses
  • Adenoviridae most adenoviruses
  • CMV cytomegalovirus
  • Poxviridae variola viruses, vaccinia viruses, pox viruses
  • Iridoviridae e.g., African swine fever virus
  • other viruses acute laryngotracheobronchitis virus Alphavirus, Kaposi's sarcoma- associated herpesvirus, Newcastle disease virus, Nipah virus, Norwalk virus, Papillomavirus, parainfluenza virus, and avian influenza.
  • Bacterial infections or diseases that can be treated or prevented are caused by bacteria including, but not limited to, Mycobacterium tuberculosis, Salmonella typhi, Bacillus anthracis, Yersinia perstis, Francisella tularensis, Legionella, Chlamydia, Rickettsia typhi, and Treponema pallidum.
  • Other bacteria that may be treated or for which the methods described herein confer protection include, but are not limited to, Pasteurella species, Staphylococci species, and Streptococcus species.
  • Gram negative bacteria include, but are not limited to, Escherichia coli, Pseudomonas species, and Salmonella species.
  • infectious bacteria include, but are not limited to, Helicobacter pyloris, Borelia burgdorferi, Mycobacteria sps (e.g. M. avium, M. intracellulare, M. kansaii, M.
  • Fungal diseases that can be treated or prevented using the poxviruses and methods described herein include, but are not limited to, Coccidioides immitis, Blastomyces dermatitidis, Cryptococcus neoformans, Candida albicans, Aspergillus species.
  • Other fungi that may be treated or for which the methods described herein confer protection include, but are not limited to: Histoplasma capsulatum, Coccidioides immitis, and Chlamydia trachomatis.
  • Protozoal diseases or infections that can be treated or prevented unclude but are not limited to, Malaria (Plasmodium falciparum,
  • Plasmodium vivax Plasmodium ovale, Plasmodium malariae
  • Leishmania species Trypanosome species (African and American)
  • cryptosporidiums isospora species
  • Naegleria fowleri Acanthamoeba species
  • Balamuthia mandrillaris Toxoplasma gondii
  • Pneumocystis carinii Pneumocystis carinii.
  • Cancers or tumors which may be treated or prevented, but are not limited to, melanoma, cutaneous squamous cell carcinoma, basal cell carcinoma, breast cancer, prostate adenocarcinoma, prostatic intraepithelial neoplasia, squamous cell lung carcinoma, lung adenocarcinoma, small cell lung carcinoma, ovary cancer of epithelial origin, colorectal adenocarcinoma and leiomyosarcoma, stomach adenocarcinoma and leiomyosarcoma, hepatocellular carcinoma, cholangiocarcinoma, ductal adenocarcinomas of pancreas, endocrine pancreatic tumors, renal cell carcinoma, transitional cell carcinoma of kidney and bladder, bladder squamous cell carcinoma, papillary thyroid cancer, follicular thyroid cancer, brain cancers
  • Modified, replication-deficient or non-replicating viral vectors expressing one or more exogenous T-cell antigens in an amount sufficient to elicit or stimulate the immune response against the antigen are administered to mechanically disrupted epidermal tissue of the subject.
  • Intranasal vaccine will generate a robust population of lung TRM, but relatively few skin, liver, or GI tract T RM - Intraperitoneal administration does not generate large populations of skin or lung T M . Intramuscular administration is ineffective at generating TRM in most tissues.
  • the adaptive immune system through the generation and maintenance of protective immunologic memory, permits people to live amongst a plethora of pathogens for many decades.
  • the body has several epithelial surfaces that interface with the environment. The most accessible is skin, but continuous with skin is the oropharyngeal mucosal epithelium, the female reproductive epithelium, and the large and complex epithelial tissues that line the respiratory and gastrointestinal tracts. For pathogens to gain access to blood and internal tissues, they must infect and then breach one or more of these epithelial barriers. While each of these epithelial tissues is structurally different and employs different innate immune defenses, the adaptive immune system mediates lifelong protection against pathogen attack, through T cell memory and B cell antibody production.
  • T cell memory As recently as five years ago, it was an article of faith that protective T cell memory was mediated by cells circulating in blood and through secondary lymphoid tissues. According to this view, while memory T cells could be readily mobilized from these compartments to peripheral epithelial tissues to captain the immunologic defense forces fighting infection, T cells were thought to return to blood and lymph nodes once the infection was resolved. Very recently, memory T cells have been found in peripheral tissues, in abundance, in both humans and mice. Because of its accessibility, the majority of human work has been done in skin. Seminal work in this area has demonstrated that twice as many T cells reside in normal, non-inflamed human skin as in blood, and there are more than 20-foid more of skin homing memory T cells cells in normal skin than in blood. These skin resident T cells (TR M ) have a diverse T cell receptor repertoire, can be readily activated through the TCR or by cytokines, and have great proliferative potential.
  • TR M skin resident T cells
  • T cells are polyfunctional with regard to cytokine production, suggesting their authentic role as memory T cells that protect against infection.
  • T cell recruitment into extranodal peripheral tissues is a highly regulated process controlled by the sequential interactions of adhesion molecules and chemokine receptors that are differentially expressed on various T cell subsets and their target.
  • Human skin-homing T cells express cutaneous lymphocyte antigen (CLA) which binds to skin microvasculature- expressed E-selectin, typically in combination with CCR4 whose ligand CCL17 (TARC) is constitutively expressed on skin endothelium.
  • Gut- homing T cells express 4 ⁇ 7 integrin and chemokine receptor CCR9, to which the corresponding ligands MadCAM-1 and CCL25 (TECK) are expressed on the endothelium and epithelium of the small intestine
  • E-lig and P-lig the functional murine equivalents of human CLA
  • E-lig and P-lig the functional murine equivalents of human CLA
  • Subsets of proliferating VV specific CD 8 T cells leave the draining inguinal node after as few as three cell divisions and migrate through blood to skin (TEM), or to other LN (TC M ), respectively.
  • vaccinia- specific T C M cells continue to proliferate, in the absence of continued antigen receptor stimulation, and acquire homing receptors consistent with the regional drainage of the LN they have migrated to; e.g., a4 7-integrin in mesenteric LN.
  • generalized CD8 T cell mediated immunity to a local challenge is acquired by systemic dissemination of activated T cells from the local draining LN.
  • the tissue homing properties of these cells then are imprinted in the respective LN environments to which they disseminate.
  • Modes of vaccine delivery play a critical role in the generation of RM-
  • Different modes of vaccine delivery can generate similar levels of antibody and TCM, but vastly different levels of TRM-
  • the presence or absence of TRM is reflected in resistance to infection, and demonstrates clearly that simply sampling blood for antibody titers and/or memory T cell abundance and function as a surrogate for protective immunity falls far short of this goal and may even be misleading.
  • Skin scarification with VACV is far and away the most effective way of generating both optimal TR populations as well as T C M, not only in skin, but also in distant epithelial tissues. Mmimicking infection through an epithelial tissue is essential to generating the robust protective immunity that the vertebrate immune system has, over millions of years, evolved to generate.
  • TBM normal skin of healthy adults contains approximately 20 billion memory T cells, nearly twice the number of T cells that are present in the entire circulation. Moreover, when the relevant skin homing T cell subset was considered, nearly 98% of TBM with a skin homing phenotype were found in skin rather than blood under normal, non-inflamed conditions.
  • These skin homing/resident T cells are all CD45RO* memory cells, predominantly ⁇ TCR*, CLA + CCR4 + , and express significant levels of CCR6, somewhat less CCR8 and CXCR6, and a subset of about 15-20% express both CD62L and CCR7.
  • T RM skin T RM are 80% TEM and 20% T CM - They contain significant numbers of TNFa and IL-17 producing ⁇ cells, as well as T cells that produce IFN- ⁇ ; relatively few cells that produce IL-4 are present.
  • TCR ⁇ antibody FACS analysis indicates that these T RM are highly diverse, and all ⁇ families are represented. Nearly half of these TR expressed the activation markers CD25 (at intermediate levels) and CD69. T M are also much more responsive to stimulation than cells from the blood.
  • T RM tissue resident cells
  • tissue resident cells are also exclusively CD45RO+, and do not bear either skin (CLA/CCR4 co expression) or gut ( ⁇ 4 ⁇ 7 integrin) homing markers, but express integrin ⁇ 4 ⁇ 7.
  • Their expression of CD69 indicates that they are true tissue resident cells, and not simply cells that are trapped in the pulmonary vasculature (peripheral blood T cells are uniformly negative for CD69, while R M in humans and mice express significant CD69)).
  • T RM Repetitive encounter with antigen through a peripheral tissue generates increasing numbers of T RM that accumulate in peripheral tissues over months, years, and decades in humans.
  • the distribution of R after immunization can be modified by administering mediators that have been shown to alter the expression of T cell homing markers.
  • mediators For example, retinoic acid has been shown to enhance the expression of gut homing markers, while reducing skin homing markers.
  • Antigens from a pathogen encountered through infected skin are presented by skin-derived dendritic cells in lymph nodes draining skin, and activate nai ' ve T cells to proliferate and force their differentiation into skin homing T cells as well as central memory T cells. These skin homing T cells rapidly traffic to skin, seeding both infected skin and normal skin.
  • TRM central memory T cells
  • lymph node an amplified population of central memory T cells can be activated in lymph node, and these in turn can differentiate into skin homing T cells and seed skin in even greater numbers.
  • the skin contains polyfunctional CD45RO+/ CLA+/CCR4+ T M enriched for common skin pathogens, such as C albicans, S aureus, Trichophyton species, P.acnes, P.ovale, HSV, as well as VACV and Yellow Fever (in vaccinated individuals), but not for common gut or lung pathogens.
  • the frequency of TRM responsive to these microorganisms will vary from individual to individual, but should be significantly higher than the frequency of responsive TCM in peripheral blood, and even higher than the frequency of responsive naive T cells.
  • the lung should contain polyfunctional CD45RO+/ VLA- 1+ T RM enriched for common lung pathogens, for example, Influenza virus, M pneumonia, S.pneumonia, Adenovirus species, Rhinovirus species
  • the gastrointestinal tract should contain polyfunctional
  • CD45RO/a4p7+ T M enriched for those specific for rotavirus, norovirus, E.coli, enteroviruses, H. pylori, calciviruses.
  • the blood contains T CM and T EM specific for all antigens found in skin, lung, and colon, as well as endogenous viruses such as CMV and EBV.
  • Most antigen reactive T cells will be non-polyfunctional TCM
  • vaccines to infectious diseases would have to be evaluated not based solely on their ability to generate a neutralizing antibody response, but rather their capacity to generate populations of antigen specific TEM and 1CM that would migrate to relevant tissues and become T .
  • Vaccines to prevent the emergence or recurrence of human cancers would have to be similarly be modified so as to generate optimal populations of TRM that would be deployed to the relevant tissue.
  • the HPV vaccine for cervical cancer might be modified to deliver TRM to reproductive mucosa.
  • Immunologically mediated diseases that involve peripheral tissues, including skin (e.g., psoriasis), lung (e.g. asthma), and gut (e.g.,
  • TRM inflammatory bowel disease
  • Modified poxviruses are preferably administered by mechanical disruption of the epidermis (e.g., by skin scarification, scratching, abrading or superficial cutting).
  • Methods and devices for disrupting the skin and for depositing a substance into the epidermis of the skin are known in the art. Examples of devices for disrupting the skin include a scarification needle, a hypodermic needle, or an abrader.
  • the device is incorporated as part of a sterile vial containing lyophilized vaccine, which is rehydrated either from a separate source of diluent or by perforating a membrane separating the vaccine from the diluent.
  • the device mechanically disrupts the epidermis (e.g., abrader) by moving or rubbing over the epidermal tissue such as the skin.
  • a chemical abrader is used, such as a surfactant to disrupt the mucosal layer in the lung, gastrointestinal tract or reproductive tract. It is preferred that the minimum amount of abrasion/mechanical disruption to produce the desired result be used. Determination of the appropriate amount of
  • abrasion/mechanical disruption for a selected poxvirus and/or composition thereof is within the ordinary skill in the art.
  • the viral vaccine may be applied in dry form to the abrading surface of the abrading device prior to application.
  • a reconstituting liquid is applied to the skin at the delivery site and the viral vaccine-coated abrading device is applied to the skin at the site of the reconstituting liquid. It is then moved or rubbed over the skin so that the poxvirus (composition) becomes dissolved in the reconstituting liquid on the surface of the skin and is delivered simultaneously with abrasion.
  • a reconstituting liquid may be contained in the device (e.g., a scarification needle, a hypodermic needle, or an abrader) and released to dissolve the viral vaccine as the device is applied to the skin for mechanical disruption of the epidermis.
  • Certain viral vaccines may also be coated on the device (e.g., abarding device) in the form of a gel.
  • the devices are preferably capable of disrupting the skin to penetrate the epidermis without penetrating the dermis. In some embodiments, the device penetrates the stratum corneum without penetrating the entire epidermis.
  • the viral vaccine to be administered using the methods described herein may be applied to the skin prior to abrading, simultaneous with abrading, or post-abrading.
  • the device In order to achieve the desired mechanical disruptions of the epidermis, the device should be moved across a subject's skin at least once.
  • the subject's skin may be disrupted in alternating directions.
  • the surface of the device may be coated with the viral vaccine.
  • the length and thickness of the microprotrusions are selected based on the particular substance being administered and the thickness of the epidermis in the location where the device is to be applied.
  • the microprotrusions penetrate the epidermis without piercing or passing through the entire dermis. In some embodiments, the protrusions penetrate the stratum corneum substantially without piercing or passing through the entire epidermis.
  • the device is moved about 2 to 15 centimeters
  • the device is moved to produce a mechanically disrupted epidermal site having a surface area of about 4 cm 2 to about 300 cm 2 .
  • the extent of the mechanical disruption of the epidermis is dependent on the pressure applied during movement and the number of repetitions with the device.
  • devices such as a scarification needle or an abrader for accurately targeting the epidermal space are provided. These devices may have solid or hollow microprotrusions.
  • the microprotrusions can have a length up to about 1500 microns. In some embodiments, the microprotrusions have a length of about 200 to 1500 microns. In some embodiments, the microprotrusions have a length of about 300 to 1000 microns, or in the range of about 400 to 800 microns.
  • Microneedle devices for administration of vaccine are available from BioSeren Tach Inc and described in U.S. Patent No. 6,334,856. Skin patches are described in U.S. Patent No. 6,706,693. These devices can be made of a biocompatible polymer or metal.
  • MEMS microelectromechanical
  • an immune response to the antigen can be generated by administering between about 100-fold to about a 100-fold less pfu (plaque forming units) of the viral vector, when applied by mechanical disruption of the epidermis compared to conventional injection routes.
  • a specific immune response to the antigen can be generated by administering between about 90-fold, 80-fold, 70-fold, 60-fold, 50-fold, 40-fold s 30-fold, 20-fold, 10-fold, 5-fold less pfu of the viral vaccine when applied by mechanical disruption of the epidermis compared to conventional injection routes.
  • a single deposition of recombinantvirai vaccine is required to elicit a long-lasting, potent antigen- specific immune response in the subject.
  • the poxviruses and/or compositions thereof provided herein may also be administered on a dosage schedule, for example, an initial administration of a viral vaccine with subsequent booster
  • a second dose of the viral vaccine is administered anywhere from two weeks to one year, preferably from one to six months, after the initial administration.
  • a third dose may be administered after the second dose and from three months to two years, or even longer, preferably 4 to 6 months, or 6 months to one year after the initial administration.
  • the boosting antigen may be administered using the same viral vaccine, or as a whole protein, an immunogenic peptide fraction of the protein, another recombinant viral vector, or DN A encoding the protein or peptide.
  • different viral vaccines are used. For example, vaccinia may be followed by an avipox such as fowlpox, or vice versa. In some preferred embodiments, no booster immunization is required.
  • kits comprising, one or more containers filled with one or more of the following components: a live, modified, non-replicating or replication-impaired virus comprising an antigen and optionally comprising a co-stimulatory molecule, either in dried form (e.g. lyophilized), as a salt, or in a solution, optionally a second virus comprising a co-stimuiatory molecule, either in dried form (e.g. lyophilized), as a salt, or in a solution, optionally a solution or gel to dissolve or admix the virus(es), and optionally an adjuvant.
  • the kits additionally contain a device for disrupting the epidermis.
  • kit can be instructions on how to use the kit and optionally a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • in vitro assays may be used to determine the occurrence of an immune response. Examples of such in vitro assays include ELISA assays and cytotoxic T cell (CTL) assays.
  • the immune response is measured by detecting and/or quantifying the relative amount of an antibody, which specifically recognizes an antigen in the sera of a subject who has been treated by administering the live, modified, non-replicating or replication-impaired poxvirus comprising the antigen, relative to the amount of the antibody in an untreated subject.
  • the preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can be achieved by techniques which are well known to those who are skilled in the art.
  • ELISA assays may be used to determine the level of isotype specific antibodies using methods known in the art.
  • CTL assays can be used to determine the lytic activity of CTLs, measuring specific lysis of target cells expressing a certain antigen.
  • Immune- assays may be used to measure the activation (e.g., degree of activation) of sample immune cells.
  • Sample immune cells refer to immune cells contained in samples from any source, including from a human patient, human donor, animal, or tissue cultured cell line.
  • the immune cell sample can be derived from peripheral blood, lymph nodes, bone marrow, thymus, any other tissue source including in situ or excised tumor, or from tissue or organ cultures.
  • the sample may be fractionated or purified to generate or enrich a particular immune cell subset before analysis.
  • the immune cells can be separated and isolated from their source by standard techniques.
  • Immune cells include both non-resting and resting cells, and cells of the immune system that may be assayed, including, but not limited to, B lymphocytes, T lymphocytes, natural killer (NK) cells, lymphokine-activated killer (LAK) cells, monocytes, macrophages, neutrophils, granulocytes, mast cells, platelets, Langerhans cells, stem cells, dendritic cells, and peripheral blood mononuclear cells.
  • Immune cell activity that may be measured include, but is not limited to (1) cell proliferation by measuring the cell or DNA replication; (2) enhanced cytokine production, including specific measurements for cytokines, such as ylFN, GM-CSF, or TNF-alpha, IFN-alpha, IL-6, IL-10, IL-12; (3) cell mediated target killing or lysis; (4) cell differentiation; (5) immunoglobulin production; (6) phenotypic changes; (7) production of chemotactic factors or chemotaxis, meaning the ability to respond to a chemotactin with chemotaxis; (8) immunosuppression, by inhibition of the activity of some other immune cell type; (9) chemokine secretion such as IP- 10; (10) expression of costimulatory molecules (e.g., CD80, CD 86) and maturation molecules (e.g., CD83), (12) upregulation of class II MHC expression; and (13) apoptosis, which refers to fragmentation of activated immune cells under certain circumstances
  • Reporter molecules may be used for many of the immune assays described.
  • a reporter molecule is a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative.
  • the most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i. e.
  • radioisotopes and chemiluminescent molecules.
  • an enzyme immunoassay an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate.
  • glutaraldehyde or periodate As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan.
  • Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta- galactosidase and alkaline phosphatase, amongst others.
  • the substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase.
  • fluorescein and rhodamine may be chemically coupled to antibodies without altering their binding capacity.
  • the fluorochrome-labeled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labeled antibody adsorbs the light energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope.
  • the fluorescent labeled antibody is allowed to bind to the first antibody-antigen complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the antigen of interest.
  • Activated immune cell proliferation is intended to include increase in cell number, cell growth, cell division, or cell expansion, as measured by cell number, cell weight, or by incorporation of radiolabeled nucleic acids, amino acids, proteins, or other precursor molecules.
  • DNA replication is measured by incorporation of radioisotope labels.
  • cultures of stimulated immune cells can be measured by DNA synthesis by pulse-labeling the cultures with tritiated thymidine ( 3 H-Tdr), a nucleoside precursor that is incorporated into newly synthesized DNA. Thymidine incorporation provides a quantitative measure of the rate of DNA synthesis, which is usually directly proportional to the rate of cell division.
  • the amount of 3 H-labeled thymidine incorporated into the replicating DNA of cultured cells is determined by scintillation counting in a liquid scintillation spectrophotometer. Scintillation counting yields data in counts per minute (cpm) which may then be used as a standard measure of immune cell responsiveness. The cpm in resting immune cell cultures may be either subtracted from or divided into cpm of the primed immune cells, which will yield a stimulation index ratio.
  • Flow cytometry can also be used to measure proliferation by measuring DNA with light scatter, Coulter volume and fluorescence, all of which are techniques that are well known in the art.
  • a measure of immune cell stimulation is the ability of the cells to secrete cytokines, Iymphokines, or other growth factors.
  • Cytokine production including specific measurements for cytokines, such as ylFN, GM-CSF, or TNF-alpha, may be made by radioimmunoassay (RIA), enzyme-linked immunoabsorbent assay (ELISA), bioassay, or measurement of messenger UNA levels.
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • bioassay or measurement of messenger UNA levels.
  • a monoclonal antibody to the cytokine to be measured is used to specifically bind to and thus identify the cytokine.
  • Immunoassays are well known in the art and can include both competitive assays and immunometric assays, such as forward sandwich immunoassays, reverse sandwich immunoassays and simultaneous immunoassays.
  • the sample-containing cytokine is incubated with the cytokine-specific monoclonal antibody under conditions and for a period of time sufficient to allow the cytokines to bind to the monoclonal antibodies.
  • the specific concentrations of antibodies, the temperature and time of incubation, as well as other such assay conditions can be varied, depending upon various factors including the concentration of cytokine in the sample, the nature of the sample, and the like. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine
  • Immunode-mediated target cell lysis Another type of indicator for degree of immune cell activation is immune cell-mediated target cell lysis, which is meant to encompass any type of cell killing, including cytotoxic T lymphocyte activity, apoptosis, and the induction of target lysis by molecules secreted from non-resting immune cells stimulated to activity.
  • Cell-mediated lympholysi s techniques typically measure the ability of the stimulated immune cells to lyse 51 Cr-labeled target cells. Cytotoxicity is measured as a percentage of 51 Cr released in specific target cells compared to percentage of 51 Cr released from control target cells. Cell killing may also be measured by counting the number of target cells, or by quantifying an inhibition of target cell growth.
  • Cell Differentiation Assay Another indicator of immune cell activity is immune cell differentiation and maturation.
  • Cell differentiation may be assessed in several different ways. One such method is by measuring cell phenotypes. The phenotypes of immune cells and any phenotypic changes can be evaluated by flow cytometry after immunofmorescent staining using monoclonal antibodies that will bind membrane proteins characteristic of various immune cell types.
  • a second means of assessing cell differentiation is by measuring cell function. This may be done biochemically, by measuring the expression of enzymes, mRNA's, genes, proteins, or other metabolites within the cell, or secreted from the cell. Bioassays may also be used to measure functional cell differentiation.
  • Immune cells express a variety of cell surface molecules which can be detected with either monoclonal antibodies or polyclonal antisera. Immune cells that have undergone differentiation or activation can also be enumerated by staining for the presence of characteristic cell surface proteins by direct immunofluorescence in fixed smears of cultured cells.
  • Mature B cells can be measured in immunoassays, for example, by cell surface antigens including CD 19 and CD20 with monoclonal antibodies labeled with fluorochromes or enzymes may be used to these antigens.
  • B cells that have differentiated into plasma cells can be enumerated by staining for intracellular immunoglobulins by direct immunofluorescence in fixed smears of cultured cells.
  • Immunoglobulin Production Assay B cell activation results in small, but detectable, quantities of polyclonal immunoglobulins. Following several days of culture, these immunoglobulins may be measured by
  • radioimmunoassay or by enzyme-linked immunosorbent assay (ELIS A) methods.
  • enzyme-linked immunosorbent assay enzyme-linked immunosorbent assay
  • B cells that produce immunoglobulins can also be quantified by the reversed hemolytic plaque assay.
  • erythrocytes are coated with goat or rabbit anti-human immunoglobulins. These immunoglobulins are mixed with the activated immunoglobulin-producing lymphocytes and semisolid agar, and complement is added. The presence of hemolytic plaques indicates that there are immunoglobulin-producing cells.
  • Chemotactic Factor Assay Chemotactic factors are molecules which induce or inhibit immune cell migration into or out of blood vessels, tissues or organs, including cell migration factors.
  • the chemotactic factors of immune cells can be assayed by flow cytometry using labeled monoclonal antibodies to the chemotactic factor or factors being assayed.
  • Chemotactic factors may also be assayed by ELISA or other immunoassays, bioassays, messenger RNA levels, and by direct measurements, such as cell counting, of immune cell movements in specialized migration chambers.
  • autologous ex vivo activated cells exhibit an enhanced response to a "recall” antigen, which is an antigen to which the peripheral blood mononuclear cells had previously been exposed.
  • Primed or stimulated immune cells should enhance other immune cells response to a "recall” antigen when cultured together.
  • helper or additive assays.
  • primed or stimulated immune cells are added to untreated, usually autologous immune cells to determine the response of the untreated cells.
  • the added primed cells may be irradiated to prevent their proliferation, simplifying the measurement of the activity of the untreated cells.
  • These assays may be particularly useful in evaluating cells for blood exposed to virus.
  • the addback assays can measure proliferation, cytokine production, and target cell lysis as described herein.
  • the method(s) for treating or preventing cancer described herein may be used in combination with one or more anti- cancer agents.
  • the method(s) for treating or preventing infections (or diseases described herein may be used in combination with one or more anti-bacterial agents, anti-viral agents, antifungal agents, or anti-protozoal agents.
  • Example 1 Epidermal W immunization via skin scarification generates significantly stronger cellular and humoral immunity than the conventional injection routes.
  • VV vaccinia virus
  • VV skin scarification induced significantly stronger primary and memory T cell response, as well as higher serum VV-specific IgG levels, compared to the conventional injection routes (s.c, i.d., and i.m.).
  • Long-term T cell memory and serum IgG levels were comparable in VV scarified mice and i.p. immunized mice.
  • Figures 1 A-1D Thus, localized epidermal VV immunization via skin scarification achieves comparable immunogenicity compared to i.p. infection which establishes systemic viral infection, according to IFN- ⁇ response and serum IgG level.
  • Example 2 W skin scarification provides superior protection against secondary antigenic challenge.
  • the first challenge model was cutaneous poxvirus infection (via skin infection). This model was chosen for two reasons. First, clinically, the protection efficacy of smallpox vaccine candidates is evaluated by challenging vaccinated individuals with Dryvax skin scarification. Second, natural poxvirus infection can be acquired via cutaneous exposure to the viruses, especially at injured skin area. Following skin challenge, viral load in skin was determined by VV-specific real-time PC (Fig. 2). Compared to unimmunized control mice, mice immunized by s.c, i.d., and i.m. injection all demonstrated partial protection, with 15, 9.5 and 3 -fold reduction in viral load, respectively. 3-log reduction in viral load was achieved in i.p.
  • mice immunized via s.c, i.d. and i.m. injection routes (at 2 x 10 6 pfu dose) developed apparent clinical illness (manifested by the significant loss of body weight, BW), and were only partially protected from mortality.
  • mice immunized via s.s. and i.p. routes were completely protected with 100% survival and minimal BW changes.
  • skin scarification route achieved better protection efficacy than s.c, i.d. and i.m. routes even at a 1000 x lower dose (Fig. 3C,3D).
  • VV immunization via skin scarification protected respiratory mucosa more effectively than the conventional immunization routes.
  • mice C57B1/6 mice were immunized with recombinant vaccinia virus (rVV) expressing ovalbumine (OVA) K b epitope Ova 25 .264 via different routes, and challenged with B16 melanoma cells expressing OVA intradermally 5 weeks following immunization.
  • rVV recombinant vaccinia virus
  • OVA ovalbumine K b epitope Ova 25 .264
  • B16 melanoma cells expressing OVA intradermally 5 weeks following immunization.
  • s.c i.d., i.m., and i.p.
  • no visible or palpable tumor was detected on any of the skin scarified mice.
  • Example 3 Memory T ceils but not Ab are required for W skin
  • Wild type (wt) and B cell-deficient ⁇ mice were immunized with VV by skin scarification or i.p. injection, the two most immunogenic routes in this study. The memory mice were then challenged by secondary cutaneous or intranasal poxvirus infection.
  • ⁇ mice immunized via s.s. route still demonstrated strong protection against cutaneous challenge, with a viral load comparable to that of the wt mice immunized via skin scarification.
  • T cells were depleted from the wt memory mice before and during challenge (by large dose treatment with anti-CD4 and anti-CD 8 mAbs), the immune protection was completely abrogated in both s.s. and i.p. immunization groups.
  • T cell memory seemed to be more important than Ab response for the complete protection against intranasal challenge.
  • Wt and ⁇ mice were immunized with VV via skin scarification and lethally challenged with WR-VV via intranasal infection. Both strains of mice were completely protected against mortality (Fig. 6A) with minimal change of BW (Fig. 6B).
  • Fig. 6D depletion of T cells from wt memory mice led to more pronounced BW loss (Fig. 6D), although all the T cell-depleted immune mice survived the challenge (Fig. 6C).
  • Example 4 Wskin scarification generates large number of skin-homing T e j /T em , as well as T cells with highly versatile homing ability by primary and secondary tissue homing imprinting programs in regional LN.
  • antigen-specific T cells develop the highly versatile homing ability to provide systemic immune protection following a local VV infection restricted to skin was investigated by adoptively transferring naive CFSE- labeled Thyl.l* Ova 2 57-264-specific OT-I T cells into Thyl.2 + wt mice and subsequently tracking their in vivo activation, proliferation and migration following skin scarification or i.p. infection with rVV-Ova 2 57-264-
  • OT-I cells proliferated extensively within skin-draining inguinal LN (ILN) as early as 60 h following skin scarification, while similar proliferation was seen in the gut-draining mesenteric LN (MLN) after i.p. infection.
  • LN-homing molecule CD62L which is highly expressed on naive and T cm T cells circulating among secondary lymphoid tissues.
  • E-Lig Fig. 7 A
  • P-Lig P-Lig (P-selectin ligands)
  • tissue-homing molecules were upregulated after 3 cell divisions and continued to increase as a function of cell division (Fig. 7D).
  • antigen-specific T cells are imprinted with tissue-specific homing phenotype within regional LN where priming occurs (primary homing imprinting).
  • primary homing imprinting This enabled the activated T cells to migrate specifically to the infected tissues as early as day 3 after VV skin scarification.
  • This surprisingly rapid T cell recruitment into skin after primary VV skin scarification had not been previously appreciated.
  • T cells activated in skin- draining ILN migrated throughout secondary lymphoid tissues without virus or viral antigen dissemination.
  • Lymphocytes were prepared from the indicated tissues 5 days after rVV-ova skin scarification.
  • the proliferation of OT-1 cells was analyzed by flow cytometry.
  • R A samples were prepared from the indicated tissues at day 5 after VV scarification.
  • VV infection was measured by real-time RT-PCT. Data represent the averages + s.d. of 4 independent experiments with three mice per group.
  • Antigen presenting cells were purified with anti-MHC Class II magnetic beads from ILN, MLN and spleen of B6 mice 4 days following skin scarification with rVV-ova.
  • the cells were co-cultured with CFSE-labeled Thyl.l + OT-1 cells for 60 h. OT-1 cell activation and proliferation was monitored by flow cytometer. The histograms were gated on Thyl.l + population. Several additional unanticipated findings were made. In contrast to the highly specific tissue trafficking at 60 h following infection, activated OT-I cells had disseminated into non-draining LN by 5 days after rVV-ova skin scarification.
  • Gut-homing ⁇ 4 ⁇ 7 was upregulated on the proliferating OT-I cells.
  • FTY720 a functional antagonist of sphingosine 1 -phosphate that regulates lymphocyte egress from lymphoid tissues
  • Fig. 9B the expression of E-Lig on OT-I cells was unaffected
  • Fig. 9C ⁇ 4 ⁇ 7 on OT-I cells was abrogated.
  • This data strongly indicate the upregulation of gut homing molecules occurred subsequent to OT-I migration into MLN (secondary tissue homing imprinting). A similar process may happen in other non-draining LN where putative lung and mucosal trafficking molecules are expressed.
  • Example 5 MVA skin scarification represents a immunization strategy that is superior, safe and effective.
  • the highly attenuated replication-defective VV strain MVA has been actively explored as a promising live viral vaccine vector because of its impressive safety and immunogenicity profile in both preclinical and clinical studies.
  • MVA vaccines have been administered exclusively via injection routes, and never via skin scarification. This may be due to the intuitive assumption that viral replication in epidermis is required for the development of pox lesion and the subsequent strong protection against challenge.
  • mice with MVA were immunized via skin scarification.
  • MVA skin scarification induced characteristic pox lesions in a dose-dependent manner, and generated dose-dependent cellular (Fig. 1 IB) and humoral (Fig. 11 A) immune responses against VV antigens.
  • Fig. 11C MVA skin scarification provided complete protection against mortality
  • Fig. 11 D 1.8 x 10 6 pfu, a dose at which replicative VV
  • MVA skin scarification for immunocompromised hosts was confirmed in Rag-/- mice lacking both T cells and B cells.
  • MVA scarified Rag-/- mice developed small pox lesion that was confined to the site of inoculation, and survived long-term without losing any BW (Fig. 13 A, 13B) or detectable viremia (Fig. 13C).
  • VV scarified Rag-/- mice developed deteriorating skin erosion and necrosis and succumbed around 4 weeks after infection.
  • MVA skin scarification is highly effective in generating protective immunity indicates productive viral infection in epidermis is not required to achieve strong protection efficacy. However, infection of epidermis with metabolically active live virus seems to be necessary for rigorous immune response to develop.
  • a s naive OT-1 T cells proliferate in response to antigen, and a subset is imprinted with tissue homing molecules to migrate to infected skin as well as normal skin (at a lower level). Another subset leaves the draining LN after three or so cell divisions and migrates to all other LN, where these cells are secondarily imprinted with other tissue homing molecules. These cells in turn populate lung, liver, and gut.
  • T M- T are most abundant near the site of scarification, next most abundant in normal skin, and then detectable (albeit less abundant) in other epithelial peripheral tissues, where they can be detected for many months after skin scarification.
  • these TR are not simply present— they are functional and protective, as measured by their capacity to clear infectious virus from skin. Both previously immunized skin and never immunized skin in the same mouse can rapidly mount a protective immune response to re-infection in MT antibody- deficient mice, even when mobilization of central memory T cells has been blocked by the SIP-1 inhibitor FK506.
  • hypogammaglobulinemia susceptible to recurrent bacterial infections, tolerate immunization with VACV normally and develop protective iirmiunity. In contrast, those with congenital T cell defects developed severe and usually fatal complications from VACV vaccination. Moreover, immunization with inactivated VACV generated high antibody titers, but did not generate protective immunity to VACV or smallpox (Boulter, 1969). The results also indicate that scarification with heat inactivated VACV generated antibody but no IFN-gamma responses in splenic T cells, and no protection from skin challenge with VACV.
  • Example 6 Skin resident memory T cells accumulate throughout skin after repetitive antigenic challenges and provide potent recall responses.
  • vaccinia virus encoding the ovalubumin peptide OVA , was used to immunize mice
  • mice previously loaded with OT-I cells via skin scarification. 30 days later, immunized mice were surgically joined with normal mice to create parabiotic mice. Parabiotic mice allow study of the recirculation of T cells in a fashion that cannot be duplicated by other experimental modalities.
  • Parabiotic mice are surgically joined at flank skin, and their circulatory- systems undergo anastomosis, followed by free exchange of circulating blood cells as early as one week after joining.
  • Thy 1.2+ recipient C57BL/6 mice 1 day prior to 2x 10 PFU VACV-OVA skin scarification (s.s.).
  • 30 days post infection (PI) some of OT-I-bearing mice were joined surgically with naive normal Thy 1.2+ C57BL/6 mice to create OT-I : normal parabiotic mice.
  • the left OT-I-bearing mice were set as control (ctl).
  • PS time points post surgery
  • Thyl.1+ OT-I cells Thyl.1+ OT-I cells.
  • B-cell-deficient ⁇ mice were used to create OT-I : normal parabiotic mice, which were separated surgically 8 weeks PS. 2 weeks after
  • Thy 1.2+ recipient C57BL/6 mice 1 day prior to infection with 2x10 PFU VACV-OVA by s.s. route.
  • PI post-infection
  • Thy 1.1+ OT-I cells in both infected and uninfected skin were examined by flow cytometry. These experiments were repeated three times with similar data.
  • mice were infected with 2* 10 PFU VACV-OVA only on the left ears. 20 and
  • mice 30 days later, some of mice were challenged with 2x10 PFU VACV-OVA on the tail and flank skin, respectively. All infection routes are s.s.. 30 days after challenge, Thyl .1+ OT-I cells were examined by analyzing their percentages (B) and absolute numbers (C) in uninfected right ears.
  • Group 1 only
  • Thy 1.1+ OT-I cells Thy 1.1+ OT-I cells.
  • Group 2 Thy 1.1 OT-I cells + left ear infection.
  • Group 3 OT-I cells + left ear / tail / flank infections.
  • n 5 per group. **: P ⁇ 0.01.
  • mice B-cell-deficient ⁇ mice were infected with 2x10 PFU VACV by s.s. on the left ears or i.p. injection route. 7 or 30 days later, the immunized
  • mice were challenged with 2x 10 PFU VACV on both ears by s.s. route. Meanwhile, 1 mg/kg FTY720 were intraperitoneally injected each day. 6 days after challenge, virus titers in both ears were examined, n-5 per group.
  • mice were then separated at these time points, and then 2 weeks later were examined for the distribution of OT-1 TCM and TRM.
  • the results show that resting central memory T cells (T ) re-circulate freely to all secondary
  • lymphoid tissues, while skin T remain in place long term and become a
  • OT-i-bearing mice were immunized on the left ear. The accumulation of OT-I cells was then assessed in the infected (left) and uninfected (right) ears. OT-I cells were first detectable in the left ear at day 3, and also appeared in the uninfected ear, although they were less abundant. Peak recruitment to the infected and uninfected ear skin occurred at day 7, with roughly 10-fold more OT-I cells in infected than uninfected skin.
  • mice infected (as before) only on the left ear were compared to another group of mice infected first on the left ear, but then 20 days later on the tail, and 30 days later on the flank. In both groups, the number of OT-I cells in the originally infected ear was compared to the uninfected ear.
  • TCM rapidly (e.g., 2 weeks) equilibrated between the parabiotic pair in all secondary lymphoid tissues.
  • TRM remained in the skin of the scarified mouse and did not appear in the naive parabiotic partner's skin, even after 24 weeks as a parabiotic pair.
  • OT-1 cells are > 10% of CD8+ TRM in immunized skin.
  • the unimmunized parabiotic mouse there are no OT-1 TRM despite the presence of other CD8+ TRM-
  • ss immunization generates populations of T cells than can rapidly home to skin (infected skin > uninfected skin) and become skin T RM .
  • ss immunization generates T CM that migrate to LN throughout the body while still activated, and at least some of these still activated T CM are secondarily imprinted with lung, gut, and liver homing capabilities, and migrate to these peripheral tissues taking up residence there as TRM.
  • TRM the remainder of the now- resting T C M continue to re-circulate between blood and LN, and in the absence of subsequent challenge they do not differentiate and migrate into peripheral tissues.
  • TRM skin TRM remain in place for many months, diminishing slightly in numbers, but retaining their protective capacity against viral challenge. Not only immunized skin, but even skin remote from the site of ss immunization is protected by these T RM , which populate the entire skin surface.
  • T E M a e most efficiently recruited to the site of infection, since their extravasation is enhanced in inflamed skin.
  • T RM a subset remain in situ long term as T RM -
  • the results also indicate that the entire skin surface area is seeded by TEM which enter normal skin via low level expression of E selectin, CC 4 ligands, and ICAM-1 expressed in normal dermal microvasculature.
  • T EM remain in situ, becoming TR M -
  • TR M can rapidly respond to a second encounter with pathogen.
  • T R M immunologic resources.
  • a first encounter of antigen through lung, or GI tract will generate a population of TEM that homes to the entire lung, or segment of GI tract, most efficiently exiting vessels at sites of inflammation, but also populating normal un-infiamed lung and gut.
  • the number of T R in that tissue would be expected to increase, provide better and more effective rapid protection against pathogens.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Dans la présente invention, on utilise des virus atténués déficients en termes de réplication tels que des virus de la vaccine pour livrer un antigène exogène viral, bactérien, parasite ou tumoral à un tissu épidermique tel que la peau, les poumons ou le tractus gastrointestinal, qui a été mécaniquement rompu, suivant une quantité efficace pour éliciter ou stimuler une réponse immune médiée par la cellule. Le tissu épidermique peut être mécaniquement rompu au moyen d'un dispositif tel qu'une aiguille de scarification ou un dispositif abrasif. L'épiderme peut être mécaniquement rompu avant, en même temps ou immédiatement après l'administration du vaccin. Le vaccin peut être utilisé pour induire une immunité contre un agent pathogène, tel qu'un virus, une bactérie ou un parasite ou encore contre un cancer chez un individu qui est déjà atteint d'un cancer ou présente un risque de le développer. Dans certains modes de réalisation, une molécule de costimulation, un facteur de croissance, un adjuvant et/ou une cytokine est administré avant, en même temps ou après le vaccin viral. Dans certains modes de réalisation, la molécule de costimulation est co-exprimée avec l'antigène par le virus.
PCT/US2012/036114 2011-05-02 2012-05-02 Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique WO2012151272A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/099,235 US8691502B2 (en) 2008-10-31 2011-05-02 T-cell vaccination with viral vectors via mechanical epidermal disruption
US13/099,235 2011-05-02

Publications (2)

Publication Number Publication Date
WO2012151272A2 true WO2012151272A2 (fr) 2012-11-08
WO2012151272A3 WO2012151272A3 (fr) 2012-12-27

Family

ID=46168616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/036114 WO2012151272A2 (fr) 2011-05-02 2012-05-02 Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique

Country Status (1)

Country Link
WO (1) WO2012151272A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3480307A4 (fr) * 2016-05-30 2020-01-01 Astellas Pharma Inc. Nouveau virus de la vaccine génétiquement modifié
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US11344589B2 (en) 2016-05-30 2022-05-31 National University Corporation Tottori University Genetically engineered vaccinia viruses
CN114748627A (zh) * 2022-05-13 2022-07-15 中国医学科学院北京协和医院 可溶性cd58在胰腺癌预防和治疗中的应用
US11638730B2 (en) 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023077147A3 (fr) * 2021-11-01 2023-06-08 Pellis Therapeutics, Inc. Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
WO2023220283A1 (fr) * 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Adjuvant de poxvirus pour vaccination par lymphocytes t

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2034323A (en) 1978-12-18 1980-06-04 Inst Nat Sante Rech Med Production of DNA Comprising B Hepatitis Viral Genome
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
EP0308220A1 (fr) 1987-09-16 1989-03-22 Nippon Zeon Co., Ltd. Avipoxvirus recombinant
WO1989003429A1 (fr) 1987-08-28 1989-04-20 Health Research Inc. Virus recombinant de la variole avicole
WO1991019803A1 (fr) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes
US5185146A (en) 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6334856B1 (en) 1998-06-10 2002-01-01 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
US20030013190A1 (en) 2000-03-14 2003-01-16 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2569984B1 (fr) * 1984-09-12 1987-08-14 Anvar Molecule synthetique contenant une pluralite d'epitopes distincts, procede pour son obtention et application a la production de polyvaccins
GB2322130B (en) * 1997-02-13 2000-12-20 Secr Defence A vaccine against Simian Herpes B virus
US7378101B2 (en) * 2001-12-21 2008-05-27 Pfizer, Inc. Vaccine for periodontal disease
AU2005235990A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2034323A (en) 1978-12-18 1980-06-04 Inst Nat Sante Rech Med Production of DNA Comprising B Hepatitis Viral Genome
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1989003429A1 (fr) 1987-08-28 1989-04-20 Health Research Inc. Virus recombinant de la variole avicole
EP0308220A1 (fr) 1987-09-16 1989-03-22 Nippon Zeon Co., Ltd. Avipoxvirus recombinant
US5185146A (en) 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus
WO1991019803A1 (fr) 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes
US6045802A (en) 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6440422B1 (en) 1995-07-04 2002-08-27 Gsf-Forschungszentrum Fur Umwelt Und Gesenudheit Gmbh Recombinant MVA virus, and the use thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6334856B1 (en) 1998-06-10 2002-01-01 Georgia Tech Research Corporation Microneedle devices and methods of manufacture and use thereof
US20030013190A1 (en) 2000-03-14 2003-01-16 Anton Mayr Altered strain of the modified vaccinia virus ankara (mva)

Non-Patent Citations (125)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUB. CO.
AIR, PROC. NATL. ACAD. SCI. USA, vol. 78, 1981, pages 7639 - 7643
AUDIBERT ET AL., NATURE, vol. 289, 1981, pages 543
BANSAL-PAKAL ET AL., NATURE MED., vol. 7, 2001, pages 907 - 12
BEACHEY, ADV. EXP. MED. BIOL., vol. 185, 1985, pages 193
BERNHARD ET AL., SCIENCE, vol. 245, 1989, pages 301 - 304
BERTHOLET, C. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 82, 1985, pages 2096 - 2100
BHATTACHARYA-CHATTERJEE ET AL., J. OF IMMUNO SPECIFICALLY., vol. 141, 1988, pages 1398 - 1403
BINNS ET AL., J. GEN. VIROL., vol. 69, 1988, pages 1275
BOON, T. ET AL., ANNU. REV. INUNUNOL., vol. 12, 1994, pages 337 365
BOURSNELL ET AL., J. OF GEN. VIROL., vol. 71, 1990, pages 621 - 628
BOYLE ET AL., VIROLOGY, vol. 156, 1987, pages 355
BRICHARD ET AL., J. EXP. MED., vol. 178, 1993, pages 489
BRITHCARD, V. ET AL., J. EXP. MED., vol. 178, 1993, pages 489 495
BROWN ET AL., CELL, vol. 49, 1987, pages 603 - 612
BUMAL, HYBRIDOMA, vol. 7, no. 4, 1988, pages 407 - 415
BZIK ET AL., VIROLOGY, vol. 155, 1986, pages 322 - 333
CALVERT ET AL., J. OF VIROL., vol. 67, 1993, pages 3069 - 3076
CEPKO ET AL., CELL, vol. 37, 1984, pages 1053 1062
COLLINS ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 7683
CONNOR ET AL., EUR J IMMUNOL., vol. 40, no. 9, September 2010 (2010-09-01), pages 2482 - 92
COONEY ET AL., LANCET, vol. 337, 1991, pages 567 - 72
COX, A. L. ET AL., SCIENCE, vol. 264, 1994, pages 716 719
DALRYMPLE ET AL.: "Replication of Negative Strand Viruses", 1981, ELSEVIER, pages: 167
DAMASO ET AL., VIROLOGY, vol. 277, 2000, pages 439 - 49
ESPOSITO ET AL., VIROLOGY, vol. 135, 1984, pages 561
ESTIN ET AL., J. NATL. CANCER INSTIT., vol. 81, no. 6, 1989, pages 445 - 446
FALKNER; MOSS, J. VIROL., vol. 62, 1988, pages 1849
FEIZI, NATURE, vol. 314, 1985, pages 53 - 57
FENNER ET AL.: "Orthopoxviruses", 1989, ACADEMIC PRESS, INC.
FOON ET AL., PROC. AM. SOC. CLIN. ONCOL., vol. 13, 1994, pages 294
FOX B. A. ET AL., J. BIOL. RESPONSE MOD., vol. 9, 1990, pages 499 511
FRANKE ET AL., MOL. CELL. BIOL., vol. 5, 1985, pages 1918
GANEM; VARMUS, ANN. REV. BIOCHEM., vol. 56, 1987, pages 651 - 693
GARCIA ET AL., J. VIROL., 1994
GERSHON ET AL., J. GEN. VIROL., vol. 70, 1989, pages 525
GHETIE ET AL., BLOOD, vol. 83, 1994, pages 1329 - 1336
GONZALES-SCARANO ET AL., VIROLOGY, vol. 120, 1982, pages 42
GOSSEN; BUJARD, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 5547 - 5551
GRAHAM ET AL., J. INFECT. DIS., vol. 166, 1992, pages 244 - 52
GREENBERG, P. D.: "Advances in Immunology", vol. 49, 1991, ACADEMIC PRESS, INC., pages: 281 355
HAHN ET AL., VIROLOGY, vol. 162, 1988, pages 167 - 180
HELLSTROM ET AL., CANCER RES., vol. 46, 1986, pages 3917 - 3923
HELLSTROM ET AL., CANCER. RES., vol. 45, 1985, pages 2210 - 2188
HELLSTROM, K. E. ET AL., ADV. CANCER RES., vol. 12, 1969, pages 167 223
HENTTU; VIHKO, BIOCHEM. BIOPHYS. RES. COMM., vol. 160, no. 2, 1989, pages 903 - 910
HERLYN ET AL., J. CLIN. IMMUNOL., vol. 2, 1982, pages 135
HILKENS ET AL., TRENDS IN BIO. CHEM. SCI., vol. 17, 1992, pages 359
HODGE ET AL., CANCER RESEARCH, vol. 59, 1999, pages 5800 - 07
HODGE ET AL., J. NATL. CANCER INST., vol. 92, 2000, pages 1228 - 39
HOON ET AL., CANCER RES., vol. 53, 1993, pages 5244 - 5250
HOUGHTON, A. N., J. EXP. MED., vol. 180, 1994, pages 1 4
HRUBY ET AL., PNAS, vol. 80, 1983, pages 3411
HU, S. L.; HELLSTROM, I.; HELLSTROM K. E.: "Vaccines: New Approaches to Immunological Problems", 1992, BUTTERWORTH-HEINEMANN, pages: 327 343
ISRAELI ET AL., CANCER RES., vol. 53, 1993, pages 227 - 230
ITOH ET AL., NATURE, vol. 308, 1986, pages 19
JENKINS ET AL., AIDS RESEARCH AND HUMAN-RETROVIRUSES, vol. 7, 1991, pages 991 - 998
KANTOR, 3. ET AL., CANCER RES., vol. 52, 1992, pages 6917 6925
KANTOR, 3. ET AL., J. NATL. CANCER INST., vol. 84, 1992, pages 1084 1091
KARNS ET AL., MBC BIOTECHNOLOGY, vol. 1, 2001, pages 11
KAWAKAMI ET AL., J. EXP. MED., vol. 180, 1994, pages 347 - 352
KAWAKAMI ET AL., PROC. NAT'L. ACAD. SCI. U.S.A., vol. 91, 1994, pages 6458 - 6462
KAWAKAMI, Y. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 3515 3519
KAWAKAMI, Y. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 6458 6462
KIENY ET AL., NATURE, vol. 312, 1984, pages 163 - 6
KILPATRICK ET AL., VIROLOGY, vol. 143, 1985, pages 399
LIU ET AL., IMMUNITY, vol. 25, no. 3, 2006, pages 511 - 20
LIU ET AL., J.VIROL., vol. 79, no. 12, 2005, pages 7363 - 70
LIU ET AL., NATURE MEDICINE, vol. 16, no. 2, 17 January 2010 (2010-01-17), pages 224 - 7
LIVINGSTON ET AL., J. CLIN. ONCOL., vol. 12, 1994, pages 1036 - 1044
LOWE ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 3896 3900
LYTVYN ET AL., J. GEN. VIROL., vol. 73, 1992, pages 3235 - 3240
MACKETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 7415
MACKETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 7415 - 7419
MACKETT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 7415 7419
MASOPUST ET AL., J EXP MED., vol. 207, no. 3, 15 February 2010 (2010-02-15), pages 553 - 64
MATHEWS; ROEHRIG, J. IMMUNOL., vol. 129, 1982, pages 2763
MATSUNO; INOUYE, INFECTION AND IMMUNITY, vol. 39, 1983, pages 155
MAYR ET AL., ZBL. BAKT. HYG. I, ABT. ORG. B, vol. 167, 1987, pages 375 - 390
MAYR, A. ET AL., INFECTION, vol. 3, 1975, pages 6 - 14
MAYR, A.; DANNER, K., DCV. BIOL. STAND., vol. 41, 1978, pages 225 - 34
MCYER, H. ET AL., J. OF GENERAL VIROLOGY, vol. 72, 1991, pages 1031 - 1038
MEYER, H. ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038
MILLER; WHELAN, HUMAN GENE THERAPY, vol. 8, 1997, pages 803 - 815
MITTELMAN ET AL., J. CLIN. INVEST., vol. 86, 1990, pages 2136 - 2144
MORIN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 4626 4630
MURARO, R. ET AL., CANCER RES., vol. 45, 1985, pages 5769 5780
NATALI ET AL., CANCER, vol. 59, 1987, pages 55 - 63
NEURATH ET AL., VACCINE, vol. 4, 1986, pages 34
NEWTON ET AL., VIROLOGY, vol. 128, 1983, pages 495 - 501
PANICALI ET AL., GENE, vol. 47, 1986, pages 193
PANICALI ET AL., GENE, vol. 47, 1986, pages 193 199
PANICALI; PAOLETTI, PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 4927 4931
PARDOLL, D. M., NATURE, vol. 369, 1994, pages 357 358
PEREZ; WALKER, J. IMMUNOL., vol. 142, 1990, pages 3662 - 3667
PUTNEY ET AL., SCIENCE, vol. 234, 1986, pages 1392 - 1395
RAGNHAMMAR ET AL., INT. J. CANCER, vol. 53, 1993, pages 751 - 758
REFFET, BLOOD, vol. 83, 1994, pages 435 - 445
ROBBINS, P. F. ET AL., CANCER RES., vol. 51, 1991, pages 3657 3662
ROSEL ET AL., J. VIROL., vol. 60, 1986, pages 436 - 449
ROTA ET AL., VIROLOGY, vol. 188, 1992, pages 135 - 142
ROTHBARD; SCHOOLNIK, ADV. EXP. MED. BIOL., vol. 185, 1985, pages 247
SALEH ET AL., J. IMMUNOL., vol. 151, 1993, pages 3390 - 3398
SCHEIFLINGER ET AL., PROC. NATL. ACAD. SCI. (USA, vol. 89, 1992, pages 9977 9981
SCHNITZLEIN ET AL., J. VIROLOGICAL METHODS, vol. 20, 1988, pages 341
SGOUROS ET AL., J. NUCL. MED., vol. 34, 1993, pages 422 - 430
SHITARA ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 36, 1993, pages 373 - 380
SHOKELT ET AL., PROC. NATL. ACAD. SCI. USA, vol. 92, 1995, pages 6522 - 6526
SMITH ET AL., NATURE, vol. 302, 1983, pages 490 - 5
SMITH ET AL., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 7155 - 9
SPYROPOULOS ET AL., J. VIROL., vol. 62, 1988, pages 1046
STICKL ET AL., DTSCH. MED. WSCHR., vol. 99, 1974, pages 2386 - 2392
SUTTER ET AL., VACCINE, vol. 12, no. 11, 1994, pages 1032 - 1040
TAILOR ET AL., NUCL. ACIDS RES., vol. 18, no. 16, 1990, pages 4928
TAYLOR ET AL., VACCINE, vol. 6, 1988, pages 497 - 503
TIOLLAIS ET AL., NATURE, vol. 317, 1985, pages 489 - 495
UPTON ET AL., J. VIROLOGY, vol. 60, 1986, pages 920
VIJAYASARDAHL ET AL., J. EXP. MED., vol. 171, no. 4, 1990, pages 1375 - 1380
WACHSMAN ET AL., J. OF INF. DIS., vol. 155, 1987, pages 1188 - 1197
WEIR ET AL., J. VIROL., vol. 46, 1983, pages 530
WITTEK, J. VIROL., vol. 49, 1984, pages 371 - 378
YAO ET AL., HUMAN GENE THER., vol. 9, 1998, pages 1939 - 1950
YOKATA ET AL., CANCER RES., vol. 52, 1992, pages 3402 - 3408
YU ET AL., CANCER RES., vol. 51, no. 2, 1991, pages 468 - 475
ZAGURY ET AL., NATURE, vol. 326, 1987, pages 249 - 50

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3480307A4 (fr) * 2016-05-30 2020-01-01 Astellas Pharma Inc. Nouveau virus de la vaccine génétiquement modifié
US10888594B2 (en) 2016-05-30 2021-01-12 National University Corporation Tottori University Genetically engineered vaccinia viruses
US11344589B2 (en) 2016-05-30 2022-05-31 National University Corporation Tottori University Genetically engineered vaccinia viruses
AU2017272721B2 (en) * 2016-05-30 2023-03-30 Astellas Pharma Inc. Novel genetically engineered vaccinia viruses
US11638730B2 (en) 2018-09-26 2023-05-02 Astellas Pharma Inc. Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
WO2023077147A3 (fr) * 2021-11-01 2023-06-08 Pellis Therapeutics, Inc. Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
WO2023220283A1 (fr) * 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Adjuvant de poxvirus pour vaccination par lymphocytes t
CN114748627A (zh) * 2022-05-13 2022-07-15 中国医学科学院北京协和医院 可溶性cd58在胰腺癌预防和治疗中的应用
CN114748627B (zh) * 2022-05-13 2023-10-27 中国医学科学院北京协和医院 可溶性cd58在胰腺癌预防和治疗中的应用

Also Published As

Publication number Publication date
WO2012151272A3 (fr) 2012-12-27

Similar Documents

Publication Publication Date Title
US9416371B2 (en) T-cell vaccination with viral vectors via mechanical epidermal disruption
JP6130876B2 (ja) 複製欠損性組換えウイルスワクチン中の抗原に対する細胞傷害性ｔ細胞応答に有利である反復ワクチン接種と組み合わされた最適化初期−後期プロモーター
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
JP6706656B2 (ja) Ｕｌ１２８複合体の送達及びｃｍｖ感染の予防のためのｍｖａワクチン
US11345928B2 (en) Modified immunization vectors
US20070160627A1 (en) Modified vaccinia virus ankara (MVA) mutant and use thereof
US10111946B2 (en) Poxviral vectors for low antibody response after a first priming immunization
WO2012151272A2 (fr) Vaccination avec des lymphocytes t à l'aide de vecteurs viraux par rupture épidermique mécanique
JP5588990B2 (ja) 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
US8535687B2 (en) Smallpox DNA vaccine and the antigens therein that elicit an immune response
US9163237B2 (en) Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
Nörder et al. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model
WO2023077147A2 (fr) Vaccins à lymphocytes t pour patients présentant une immunité humorale réduite
Zajac et al. MVAΔ008 viral vector encoding the model protein OVA induces improved immune response against the heterologous antigen and equal levels of protection in a mice tumor model than the conventional MVA
Green et al. Long term recall of memory CD8 T cells in mice to first and third generation smallpox vaccines
JP5917626B2 (ja) 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
US20230364227A1 (en) Poxvirus adjuvant for t-cell vaccination
Boudet et al. Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations
AU2017228587B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
EA045254B1 (ru) Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12723774

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12723774

Country of ref document: EP

Kind code of ref document: A2